university management research paper

• Youth Program
• Wharton Online

Research Papers | Publications

• Browse All Articles
• Newsletter Sign-Up

Management →

• 02 Apr 2024
• What Do You Think?

What's Enough to Make Us Happy?

Experts say happiness is often derived by a combination of good health, financial wellbeing, and solid relationships with family and friends. But are we forgetting to take stock of whether we have enough of these things? asks James Heskett. Open for comment; 0 Comments.

• Research & Ideas

Employees Out Sick? Inside One Company's Creative Approach to Staying Productive

Regular absenteeism can hobble output and even bring down a business. But fostering a collaborative culture that brings managers together can help companies weather surges of sick days and no-shows. Research by Jorge Tamayo shows how.

• 12 Mar 2024

Publish or Perish: What the Research Says About Productivity in Academia

Universities tend to evaluate professors based on their research output, but does that measure reflect the realities of higher ed? A study of 4,300 professors by Kyle Myers, Karim Lakhani, and colleagues probes the time demands, risk appetite, and compensation of faculty.

• 29 Feb 2024

Beyond Goals: David Beckham's Playbook for Mobilizing Star Talent

Reach soccer's pinnacle. Become a global brand. Buy a team. Sign Lionel Messi. David Beckham makes success look as easy as his epic free kicks. But leveraging world-class talent takes discipline and deft decision-making, as case studies by Anita Elberse reveal. What could other businesses learn from his ascent?

• 16 Feb 2024

Is Your Workplace Biased Against Introverts?

Extroverts are more likely to express their passion outwardly, giving them a leg up when it comes to raises and promotions, according to research by Jon Jachimowicz. Introverts are just as motivated and excited about their work, but show it differently. How can managers challenge their assumptions?

• 05 Feb 2024

The Middle Manager of the Future: More Coaching, Less Commanding

Skilled middle managers foster collaboration, inspire employees, and link important functions at companies. An analysis of more than 35 million job postings by Letian Zhang paints a counterintuitive picture of today's midlevel manager. Could these roles provide an innovation edge?

• 24 Jan 2024

Why Boeing’s Problems with the 737 MAX Began More Than 25 Years Ago

Aggressive cost cutting and rocky leadership changes have eroded the culture at Boeing, a company once admired for its engineering rigor, says Bill George. What will it take to repair the reputational damage wrought by years of crises involving its 737 MAX?

• 16 Jan 2024
• Cold Call Podcast

How SolarWinds Responded to the 2020 SUNBURST Cyberattack

In December of 2020, SolarWinds learned that they had fallen victim to hackers. Unknown actors had inserted malware called SUNBURST into a software update, potentially granting hackers access to thousands of its customers’ data, including government agencies across the globe and the US military. General Counsel Jason Bliss needed to orchestrate the company’s response without knowing how many of its 300,000 customers had been affected, or how severely. What’s more, the existing CEO was scheduled to step down and incoming CEO Sudhakar Ramakrishna had yet to come on board. Bliss needed to immediately communicate the company’s action plan with customers and the media. In this episode of Cold Call, Professor Frank Nagle discusses SolarWinds’ response to this supply chain attack in the case, “SolarWinds Confronts SUNBURST.”

• 02 Jan 2024

Do Boomerang CEOs Get a Bad Rap?

Several companies have brought back formerly successful CEOs in hopes of breathing new life into their organizations—with mixed results. But are we even measuring the boomerang CEOs' performance properly? asks James Heskett. Open for comment; 0 Comments.

• 12 Dec 2023

COVID Tested Global Supply Chains. Here’s How They’ve Adapted

A global supply chain reshuffling is underway as companies seek to diversify their distribution networks in response to pandemic-related shocks, says research by Laura Alfaro. What do these shifts mean for American businesses and buyers?

• 05 Dec 2023

What Founders Get Wrong about Sales and Marketing

Which sales candidate is a startup’s ideal first hire? What marketing channels are best to invest in? How aggressively should an executive team align sales with customer success? Senior Lecturer Mark Roberge discusses how early-stage founders, sales leaders, and marketing executives can address these challenges as they grow their ventures in the case, “Entrepreneurial Sales and Marketing Vignettes.”

• 31 Oct 2023

Checking Your Ethics: Would You Speak Up in These 3 Sticky Situations?

Would you complain about a client who verbally abuses their staff? Would you admit to cutting corners on your work? The answers aren't always clear, says David Fubini, who tackles tricky scenarios in a series of case studies and offers his advice from the field.

• 12 Sep 2023

Can Remote Surgeries Digitally Transform Operating Rooms?

Launched in 2016, Proximie was a platform that enabled clinicians, proctors, and medical device company personnel to be virtually present in operating rooms, where they would use mixed reality and digital audio and visual tools to communicate with, mentor, assist, and observe those performing medical procedures. The goal was to improve patient outcomes. The company had grown quickly, and its technology had been used in tens of thousands of procedures in more than 50 countries and 500 hospitals. It had raised close to $50 million in equity financing and was now entering strategic partnerships to broaden its reach. Nadine Hachach-Haram, founder and CEO of Proximie, aspired for Proximie to become a platform that powered every operating room in the world, but she had to carefully consider the company’s partnership and data strategies in order to scale. What approach would position the company best for the next stage of growth? Harvard Business School associate professor Ariel Stern discusses creating value in health care through a digital transformation of operating rooms in her case, “Proximie: Using XR Technology to Create Borderless Operating Rooms.”

• 28 Aug 2023

The Clock Is Ticking: 3 Ways to Manage Your Time Better

Life is short. Are you using your time wisely? Leslie Perlow, Arthur Brooks, and DJ DiDonna offer time management advice to help you work smarter and live happier.

• 15 Aug 2023

Ryan Serhant: How to Manage Your Time for Happiness

Real estate entrepreneur, television star, husband, and father Ryan Serhant is incredibly busy and successful. He starts his days at 4:00 am and often doesn’t end them until 11:00 pm. But, it wasn’t always like that. In 2020, just a few months after the US began to shut down in order to prevent the spread of the Covid-19 virus, Serhant had time to reflect on his career as a real estate broker in New York City, wondering if the period of selling real estate at record highs was over. He considered whether he should stay at his current real estate brokerage or launch his own brokerage during a pandemic? Each option had very different implications for his time and flexibility. Professor Ashley Whillans and her co-author Hawken Lord (MBA 2023) discuss Serhant’s time management techniques and consider the lessons we can all learn about making time our most valuable commodity in the case, “Ryan Serhant: Time Management for Repeatable Success.”

• 08 Aug 2023

The Rise of Employee Analytics: Productivity Dream or Micromanagement Nightmare?

"People analytics"—using employee data to make management decisions—could soon transform the workplace and hiring, but implementation will be critical, says Jeffrey Polzer. After all, do managers really need to know about employees' every keystroke?

• 01 Aug 2023

Can Business Transform Primary Health Care Across Africa?

mPharma, headquartered in Ghana, is trying to create the largest pan-African health care company. Their mission is to provide primary care and a reliable and fairly priced supply of drugs in the nine African countries where they operate. Co-founder and CEO Gregory Rockson needs to decide which component of strategy to prioritize in the next three years. His options include launching a telemedicine program, expanding his pharmacies across the continent, and creating a new payment program to cover the cost of common medications. Rockson cares deeply about health equity, but his venture capital-financed company also must be profitable. Which option should he focus on expanding? Harvard Business School Professor Regina Herzlinger and case protagonist Gregory Rockson discuss the important role business plays in improving health care in the case, “mPharma: Scaling Access to Affordable Primary Care in Africa.”

• 05 Jul 2023

How Unilever Is Preparing for the Future of Work

Launched in 2016, Unilever’s Future of Work initiative aimed to accelerate the speed of change throughout the organization and prepare its workforce for a digitalized and highly automated era. But despite its success over the last three years, the program still faces significant challenges in its implementation. How should Unilever, one of the world's largest consumer goods companies, best prepare and upscale its workforce for the future? How should Unilever adapt and accelerate the speed of change throughout the organization? Is it even possible to lead a systematic, agile workforce transformation across several geographies while accounting for local context? Harvard Business School professor and faculty co-chair of the Managing the Future of Work Project William Kerr and Patrick Hull, Unilever’s vice president of global learning and future of work, discuss how rapid advances in artificial intelligence, machine learning, and automation are changing the nature of work in the case, “Unilever's Response to the Future of Work.”

How Are Middle Managers Falling Down Most Often on Employee Inclusion?

Companies are struggling to retain employees from underrepresented groups, many of whom don't feel heard in the workplace. What do managers need to do to build truly inclusive teams? asks James Heskett. Open for comment; 0 Comments.

• 20 Jun 2023

Elon Musk’s Twitter Takeover: Lessons in Strategic Change

In late October 2022, Elon Musk officially took Twitter private and became the company’s majority shareholder, finally ending a months-long acquisition saga. He appointed himself CEO and brought in his own team to clean house. Musk needed to take decisive steps to succeed against the major opposition to his leadership from both inside and outside the company. Twitter employees circulated an open letter protesting expected layoffs, advertising agencies advised their clients to pause spending on Twitter, and EU officials considered a broader Twitter ban. What short-term actions should Musk take to stabilize the situation, and how should he approach long-term strategy to turn around Twitter? Harvard Business School assistant professor Andy Wu and co-author Goran Calic, associate professor at McMaster University’s DeGroote School of Business, discuss Twitter as a microcosm for the future of media and information in their case, “Twitter Turnaround and Elon Musk.”

Harvard University Theses, Dissertations, and Prize Papers

The Harvard University Archives ’ collection of theses, dissertations, and prize papers document the wide range of academic research undertaken by Harvard students over the course of the University’s history.

Beyond their value as pieces of original research, these collections document the history of American higher education, chronicling both the growth of Harvard as a major research institution as well as the development of numerous academic fields. They are also an important source of biographical information, offering insight into the academic careers of the authors.

Spanning from the ‘theses and quaestiones’ of the 17th and 18th centuries to the current yearly output of student research, they include both the first Harvard Ph.D. dissertation (by William Byerly, Ph.D . 1873) and the dissertation of the first woman to earn a doctorate from Harvard ( Lorna Myrtle Hodgkinson , Ed.D. 1922).

Other highlights include:

• The collection of Mathematical theses, 1782-1839
• The 1895 Ph.D. dissertation of W.E.B. Du Bois, The suppression of the African slave trade in the United States, 1638-1871
• Ph.D. dissertations of astronomer Cecilia Payne-Gaposchkin (Ph.D. 1925) and physicist John Hasbrouck Van Vleck (Ph.D. 1922)
• Undergraduate honors theses of novelist John Updike (A.B. 1954), filmmaker Terrence Malick (A.B. 1966),  and U.S. poet laureate Tracy Smith (A.B. 1994)
• Undergraduate prize papers and dissertations of philosophers Ralph Waldo Emerson (A.B. 1821), George Santayana (Ph.D. 1889), and W.V. Quine (Ph.D. 1932)
• Undergraduate honors theses of U.S. President John F. Kennedy (A.B. 1940) and Chief Justice John Roberts (A.B. 1976)

What does a prize-winning thesis look like?

If you're a Harvard undergraduate writing your own thesis, it can be helpful to review recent prize-winning theses. The Harvard University Archives has made available for digital lending all of the Thomas Hoopes Prize winners from the 2019-2021 academic years.

Accessing These Materials

How to access materials at the Harvard University Archives

How to find and request dissertations, in person or virtually

How to find and request undergraduate honors theses

How to find and request Thomas Temple Hoopes Prize papers

How to find and request Bowdoin Prize papers

• email: Email
• Phone number 617-495-2461

Related Collections

Harvard faculty personal and professional archives, harvard student life collections: arts, sports, politics and social life, access materials at the harvard university archives.

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

• Publications
• Account settings

Preview improvements coming to the PMC website in October 2024. Learn More or Try it out now .

• Advanced Search
• Journal List
• v.8(Spec Iss 4); 2015

A review of the effectiveness of stress management skills training on academic vitality and psychological well-being of college students

P alborzkouh.

* Exceptional Children Psychology, Islamic Azad University, Central Tehran Branch, Iran

** General Psychology, Islamic Azad University, South Tehran Branch, Iran

*** General Psychology, Humanities and Social Sciences Faculty, Paradise University, Gillan Branch, Iran

**** General Psychology, Islamic Azad University, Science and Research Branch, Tehran, Iran

F Shahgholy Ghahfarokhi

***** Clinical Psychology, Islamic Azad University, Science and Research Branch Branch, Isfahan, Iran

Objective: Carrying out the appropriate psychological interventions to improve vitality and mental well-being is critical. The study was carried out to review the effectiveness of stress management training on the academic life and mental well-being of the students of Shahed University.

Methodology: The method used was quasi-experimental with a pretest-posttest plan and control group. Therefore, a total of 40 students of Shahed University of Tehran were selected by a convenience sampling method and were organized into two groups: experimental and control group. Both groups were pretested by using an academic vitality inventory and an 84-question psychological well-being inventory. Then, the experimental group received stress management skills training for ten sessions, and the control group did not receive any intervention. Next, both groups were post-tested, and the data were analyzed with SPSS-21 software by using descriptive and inferential statistical methods.

Findings: The findings showed that the stress management skills training significantly contributed to promoting the academic vitality and psychological well-being of students (p < 0.001).

Conclusions: It was concluded from this research that teaching the methods for dealing with stress was an effective strategy to help students exposed to high stress and pressure, and this was due to its high efficiency, especially when it was held in groups, had a small cost, and it was accepted by the individuals.

Introduction

Challenges during education create sources of stress for students, and put their health at risk, in a way that affects their learning abilities [ 1 ]. Therefore, paying attention to the factors that could have a positive impact on the agreeableness and could increase the positive psychological states, and as a result, the physical and psychological health of the students was of great importance.

Among the important factors that affect people’s ability to adapt to the stresses of studying era is academic vitality [ 2 ]. Academic vitality means an adaptive response to various challenges and barriers experienced during education [ 3 ]. When a person does things spontaneously, does not feel not only frustrated and tired, but also constantly feels the strength and increased energy, and overall has a sense of inner vitality [ 2 ]. Therefore, the academic life has a relationship with the individual’s adaptation to the various situations of the academic period, feelings of self-efficacy and empowerment in the face of challenges, experiencing less anxiety and depression, a sense of responsibility in dealing with the academic tasks and better academic success [ 3 ]. Despite the high importance of academic vitality in the successful confrontation with the challenging academic period, the literature review of the studies managed in Iran showed that few studies were performed on the factors promoting this important variable. Therefore, an attempt to address this research gap increased the need for the current study.

Another important positive psychological state in students is the psychological well-being. The psychological well-being factor is defined as a person’s real talents growth and has six components that are the purpose in life, positive relations with others, personal growth, self-acceptance, autonomy, and environmental mastery [ 4 ]. The purpose in life means having a purpose and direction in life and pursuing them [ 5 ]. Positive relations with the others mean having warm, satisfactory relations along with confidence and empathy [ 6 ]. Personal growth means having a sense of continuous growth and the capacity for it and having an increased sense of efficacy and wisdom [ 4 ]. Self-acceptance means having a positive attitude towards oneself and accepting the various aspects of oneself [ 6 ]. Autonomy means the feeling of self-determination, independence, and self-assessment against personal criteria [ 4 ]. Moreover, environmental mastery means a sense of competence and the ability to manage the complex environment around [ 5 ].

However, one of the most significant parts affecting the psychological health and well-being of individuals is life skills training [ 7 ]. Life skills’ training is critical for students, in a way that on this basis, many universities have started to teach life skills and stress management skills to improve the physical and psychological health of their students in the recent years [ 8 ]. The main objective of the World Health Organization regarding the creation of a life skills plan is in the field of psychological health. Therefore, different societies throughout the world try to promote the implementation and evaluation of the programs training in life skills. It focuses on the growth of mental abilities such as problem-solving, coping with emotions, self-awareness, social harmony, and stress management among children, teenagers, and even adults [ 9 ]. From the life skills, training in stress management skills is critical, because students need to deal effectively with stressful issues and factors. Accordingly, it was thought that teaching stress management skills is very efficient in improving the students’ positive psychological states, in particular, their vitality and mental well-being. Therefore, this study examined the effectiveness of the stress management skills training on the academic life and psychological well-being among Shahed University students.

Methodology

The study was quasi-experimental with a pretest-posttest. The analytical community of the study included all the students of Shahed University of Tehran in the fall of 2015, who were selected with a convenience method. For the calculation of the sample size, the appropriate sample size in experimental studies was of 15 people for each group [ 10 ]. At first, the sample size of 15 individuals was selected for each group. Then, to increase the statistical power and to manage the possible decrease in the number of participants, the sample size of 20 individuals (n = 20) was considered for each group. The sampling was voluntary non-random from among all the students studying at Shahed University. The inclusion criteria included an informed consent and the willingness to participate in the research, the ability to take part in the sessions and to collaborate in carrying out assignments, willingness to cooperate in completing the instruments, and the age range of 18 to 35 years. The exclusion criteria included the lack of desire to participate in the sessions and the absence to more than three courses in the preparation method, the lack of the ability to participate in the sessions, lack of cooperation in carrying out assignments, and receiving any training or psychological therapy that was not part of the program of this research.

The procedure of the study was that from all the students studying at Shahed University, a number was non-randomly and voluntarily selected, and if they met the inclusion criteria, they were randomly assigned to two groups: experimental and control. At the beginning and before starting the study, an informed consent was obtained from all of them to uphold moral considerations, through informing them of the aim of the study and the impact of such studies in improving their psychological status. Then, all the information of the participants were collected, and they were assured that the information would remain confidential by the researcher. Then, the experimental group received group stress management training for ten sessions, and the control group did not receive any intervention. In the end, both groups were post-tested. The protocol of stress management training sessions is presented in Table 1 .

Protocol of stress management skills training sessions

The instruments used in the study included a demographic sample page, an academic vitality questionnaire, and a psychological well-being scale (PWBS-18).

Demographic sample page: The demographic sample page included age, gender, educational level, and marital status. The sample page was prepared and evaluated by the researchers of the study.

Academic vitality questionnaire: This questionnaire was developed by Dehqanizadeh MH, Hosseinchari M (2012) [ 3 ], based on the academic vitality scale of Martin AJ, Marsh HW (2006) [ 15 ], which had four items. After various implementations of the items of the questionnaire, the final version was rewritten, and the result was that the revised version had ten items. Then the items above were again examined in a preliminary study on a sample including 186 high school students, who were chosen by using a cluster random sampling, and their psychometric properties were examined. The results of the examination showed that the obtained Cronbach’s alpha coefficient, by removing [ 3 ] item number 8, was 0.80 and the retest coefficient was 0.73. Also, the range of correlation of the elements with the total score was between 0.51 and 0.68. These results indicated that the items had a satisfactory internal consistency and stability.

Psychological well-being scale (SPWB): Riffe’s mental well-being scale [ 11 ] was made up of 84 questions in Likert’s 7-degree scale (from “strongly disagree” to “agree strongly”). It was a self-report questionnaire, which measured six components of the psychological well-being, including purpose in life, positive relations with others, personal growth, self-acceptance, autonomy, and environmental mastery. The internal consistency coefficients for the components of this questionnaire were obtained from 0.83 to 0.91. In Mohammadpour and Joshanloo research (2014) [ 6 ], the reliability coefficient of this scale with Cronbach’s alpha method for the psychological well-being scale obtained was 0.81. Also, for the subscales of the test including self-compliance, environmental mastery, personal growth and development, link with others, the goal in life, and self-acceptance were obtained at 0.60, 0.64, 0.54, 0.58, 0.65, and 0.61, respectively. A study performed by Kafka and Kozma (2002) was conducted to verify the validity of the items of the Riffe’s psychological well-being scale. The findings showed that there was a high correlation between this scale and the subjective well-being scale (SWB) and the satisfaction with life scale (SWLS). In the present study, the reliability coefficient with Cronbach’s alpha method for the psychological well-being scale obtained was 0.81. Also, for the subscales of the test, including self-compliance, environmental mastery, personal growth and development, relations with others, the goal in life, and self-acceptance were obtained at 0.60, 0.64, 0.54, 0.58, 0.65, and 0.61, respectively.

The SPSS-20 software was used for data analysis. The statistical method used for the data analysis of the research on the level of descriptive statistics was mean, standard deviation, frequency, and frequency percentage indexes, and on the inferential statistics, univariate and multivariate analysis of covariance model were used.

Findings of the research

The demographic properties of the sample present in the study are presented in Table 2 .

Demographic characteristics of the subjects

As presented in Table 1 , the largest frequency of participation belonged to the participants in the age range of 21 to 25 with 14 individuals (35%) and the lowest frequency of individuals in the range of 18 to 20 years, with six individuals (15%). In addition, the mean age of the participants was 24.85, and the standard deviation was 4.41. The other information about the demographic properties of the present sample is provided in Table 2

As shown in Table 3 , the mean scores of purpose in life, positive relations with others, personal growth, self-acceptance, autonomy, environmental mastery, total score of psychological well-being, and academic vitality of posttest were increased in the test group as associated with the control group.

Descriptive stats of academic vitality and psychological well-being scores of the two groups divided by the pretest and posttest

As shown in Table 4 , the null hypothesis of the equality of variances of the two groups in the academic vitality and psychological well-being with all its components was confirmed. It meant that the variances of the two clusters in the population were equal and had no significant difference for the academic vitality and the psychological well-being variable with all its components. Thus, given the compliance with the Levene assumption, the analysis of covariance of the results of the hypothesis of the research were permitted.

Results of Levene test for the examination of the consistency of variances of academic vitality and psychological well-being variables with its components in the posttest stage

As shown in Table 5 , the significance level of all the tests (p < 0.001) indicated that there was a significant difference between the two groups at least in one of the dependent variables (academic vitality and psychological well-being with its components). And, according to the eta square, 0.89 percent of the differences observed among individuals were associated with the effect of the independent variable, which was the intervention method (stress management skills training). On the other hand, given that the statistical power was 0.95, which was higher than 0.80, the sample size was acceptable for the research. The results related to significant differences in any of the dependent variables are listed below.

Results of multivariate analysis of covariance on the scores of posttest with the control of pretest in the academic vitality and psychological well-being variable with its components

According to Table 6 , the significance level was p < 0.001, the hypothesis of the difference between the academic vitality and the psychological well-being with its components in the two groups was confirmed. It stated that 0.54, 0.25, 0.52, 0.64, 0.60, 0.59, 0.45 and 0.81 percent change in the academic vitality, individuals’ purpose in life, positive relations with others, personal growth, self-acceptance, autonomy, environmental mastery, and psychological well-being scores were due to the independent variable (stress management skills training). Therefore, it could be said that stress management skills training increased the academic vitality and the psychological well-being and all of its components.

The results of multivariate analysis of covariance to assess the impact of stress management skills training on the level of psychological well-being and its components in the posttest stage

Discussion and conclusions

Given the aim of this study, which was to examine the effectiveness of stress management skills training on the academic vitality and psychological well-being of the students of Shahed University, the results of the univariate and multivariate analysis of covariance showed that stress management skills training had a significant impact on increasing the academic vitality and psychological well-being. The findings indicated that the stress management skills training had a major impact on increasing the academic life. It was consistent with different studies of Habibi M (2015), Pakdaman A, Ganji K, Ahmadzadeh M (2012), Shirbim Z, Sudani M, Shafi-Abadi A (2008) [ 12 - 14 ].

In explaining their similar finding, Pakdaman A, Ganji K, Ahmadzadeh M (2012) [ 13 ] also stated that life skills training helped in the improvement of the academic conditions of the subjects. In addition, this was because of this training, with growing different skills of the students, helping the students know their strengths and weaknesses, and overall, help the individuals move from weaknesses and skill deficits to capable and strong skills. Therefore, this could provide the students with better educational conditions [ 14 ]. In explaining their similar finding, Shafi-Abadi (2008) stated that teaching life skills, including stress management skills, are one of the ways to improve the mental health of the individuals of the community and to prevent harms. In fact, these teachings protected the health and mental hygiene of the society and protected it against diseases, disabilities, and disturbances in human relations. As a result, the feeling of security and solidarity increased among the members of the society, and then their senses of happiness, vitality, and health increased.

The findings showed that stress management skills’ training has a significant impact on the psychological well-being. It was consistent with the multiple studies of Qadiri-Bahramabadi F, Mikaeli-Manee F (2015), Qanbari N, Habibi M, Shams-Aldini S (2013), Alavi-Arjmand N, Kashaninia Z, Hosseini MA, Reza-Soltani P (2012), Chubforushzadeh A, Kalantari M, Molavi H (2009) [ 16 - 19 ].

In explaining their similar findings, Qadiri-Bahramabadi F, Mikaeli-Manee F (2015) [ 16 ] stated that facing numerous stresses required teaching and learning of appropriate stress management skills. In other words, during stress, individuals must know the necessary coping skills to reduce the effects of stress, and if the pressure was managed and the effective coping skills were applied, the person would be able to get along better with the needs and challenges of his/ her life. Therefore, the intervention of stress management led to the formation of good feelings about oneself, as well as a positive performance in the stable world. It created interest and motivation in people’s lives as well as increasing the self-confidence of the individuals. As a result, it increased the psychological well-being.

In explaining their similar finding, Qanbari N, Habibi M, Shams-Aldini S (2013) [ 17 ] stated that with the help of multiple strategies to manage stress such as relaxation, and muscular relaxation, stress and anxiety could be reduced. The individuals identified the somatic symptoms, and with mastering the ways to acquire relaxation, which was inconsistent with stress, reduced their anxiety and unpleasant feelings, thus increasing the psychological well-being. Also, in explaining their similar finding, Chubforushzadeh A, Kalantari M, Molavi H (2009) [ 19 ], stated that stress management treatments make multiple changes in the individual’s beliefs, feelings, and behaviors. Therefore, improving the individual’s evaluations and coping skills, and the provided practices to integrate the learned separations with real life situations could lead to a decrease in the perceived stress and an increase in the psychological well-being.

Acknowledgement

The authors would like to thank the venerable authorities of Shahed University of Tehran for their assistance. Also, the authors would like to thank all the participants in the study.

•   UoN Digital Repository Home

Research Papers

By Issue Date Authors Titles Subjects

Search within this community and its collections:

Sub-communities within this community

Faculty of agriculture & veterinary medicine (fag / fvm) [293], faculty of arts & social sciences (foa&ss / fol / fbm) [1544], faculty of education (fed) [24], faculty of engineering, built environment & design (feng / fbd) [242], faculty of health sciences (fhs) [36], faculty of science & technology (fst) [194], collections in this community, district cultural profiles [0], ongoing research [16], test data [0], recent submissions, effect of african union activities on political and economic development of african countries: a case study of kenya , participatory approaches and performance of community water projects- a case of world bank funded programme water projects in garissa county, kenya , effectiveness of conflict early warning system as a framework for conflict prevention in africa. case study of south sudan , meanings of gendered lexical contrasts in kenyan english usage , assessment of biomass potential for sustainable charcoal production in kajiado county;towards informed policy decisions , development of a ready-to-eat sorghum snack supplemented with sesame and baobab fruit for nutritional and sensory quality , a cybersecurity assessment of the remote working environment during covid-19. a case study of financial regulators in kenya , strategic management practices within pharmaceutical distributors in kenya , influence of principals' management practices on teachers' job satisfaction in public secondary schools in isiolo sub-county, in kenya. , framework for effective management of cyber security on e-learning platforms in public universities in kenya , an assessment of the adoption of robotic process automation in kenyan insurance companies , on decomposition of operators in hilbert spaces , strategic management practices and organizational culture among microfinance institutions in kenya , ai chatbot: improve efficiency in handling student queries at the department of computing and informatics, nairobi university , climate change and violent conflict: a case study of puntland state of somalia (2008-2020) , influence of gemba-kaizen strategy on performance of bamburi cement plc in kenya , effect of online working on employee job satisfaction among large commercial banks in nairobi city county, kenya , the contribution of trust in quality groundnuts seed selection and sourcing among small-holder farmers in uganda , bainishaji na ukombozi wa mwanamke katika riwaya mbili za k.w. wamitila nguvu ya sala (1999) na dharau ya ini (2007) , perceptions of political leaders' utterances and their influence on inter-ethnic relations in kasarani sub-county nairobi city county, kenya .

Academia.edu no longer supports Internet Explorer.

To browse Academia.edu and the wider internet faster and more securely, please take a few seconds to  upgrade your browser .

•  We're Hiring!
•  Help Center
•   All Departments
• 88 Documents
• 302 Researchers
• Save to Library
• Next ›
• Last »

Enter the email address you signed up with and we'll email you a reset link.

• Academia.edu Publishing
•   We're Hiring!
•   Help Center
• Find new research papers in:
• Health Sciences
• Earth Sciences
• Cognitive Science
• Mathematics
• Computer Science
• Academia ©2024

Help | Advanced Search

Computer Science > Computation and Language

Title: realm: reference resolution as language modeling.

Abstract: Reference resolution is an important problem, one that is essential to understand and successfully handle context of different kinds. This context includes both previous turns and context that pertains to non-conversational entities, such as entities on the user's screen or those running in the background. While LLMs have been shown to be extremely powerful for a variety of tasks, their use in reference resolution, particularly for non-conversational entities, remains underutilized. This paper demonstrates how LLMs can be used to create an extremely effective system to resolve references of various types, by showing how reference resolution can be converted into a language modeling problem, despite involving forms of entities like those on screen that are not traditionally conducive to being reduced to a text-only modality. We demonstrate large improvements over an existing system with similar functionality across different types of references, with our smallest model obtaining absolute gains of over 5% for on-screen references. We also benchmark against GPT-3.5 and GPT-4, with our smallest model achieving performance comparable to that of GPT-4, and our larger models substantially outperforming it.

Submission history

Access paper:.

• HTML (experimental)
• Other Formats

References & Citations

• Google Scholar
• Semantic Scholar

BibTeX formatted citation

Bibliographic and Citation Tools

Code, data and media associated with this article, recommenders and search tools.

• Institution

arXivLabs: experimental projects with community collaborators

arXivLabs is a framework that allows collaborators to develop and share new arXiv features directly on our website.

Both individuals and organizations that work with arXivLabs have embraced and accepted our values of openness, community, excellence, and user data privacy. arXiv is committed to these values and only works with partners that adhere to them.

Have an idea for a project that will add value for arXiv's community? Learn more about arXivLabs .

Advertisement

Update on the clinical use of trabecular bone score (TBS) in the management of osteoporosis: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), and the International Osteoporosis Foundation (IOF) under the auspices of WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Aging

• Position Paper
• Open access
• Published: 01 July 2023
• Volume 34 , pages 1501–1529, ( 2023 )

Cite this article

You have full access to this open access article

• Enisa Shevroja   ORCID: orcid.org/0000-0001-6338-2948 1 ,
• Jean-Yves Reginster   ORCID: orcid.org/0000-0001-6290-752X 2 , 3 ,
• Olivier Lamy   ORCID: orcid.org/0000-0003-3684-2376 1 ,
• Nasser Al-Daghri   ORCID: orcid.org/0000-0001-5472-1725 4 ,
• Manju Chandran 5 ,
• Anne-Laurence Demoux-Baiada   ORCID: orcid.org/0000-0003-2616-839X 6 ,
• Lynn Kohlmeier 7 ,
• Marie-Paule Lecart 8 ,
• Daniel Messina   ORCID: orcid.org/0000-0002-7987-854X 9 ,
• Bruno Muzzi Camargos   ORCID: orcid.org/0000-0002-3132-6455 10 ,
• Juraj Payer   ORCID: orcid.org/0000-0002-4977-6817 11 , 12 ,
• Sansin Tuzun   ORCID: orcid.org/0000-0002-3300-2286 13 ,
• Nicola Veronese   ORCID: orcid.org/0000-0002-9328-289X 14 ,
• Cyrus Cooper   ORCID: orcid.org/0000-0003-3510-0709 15 , 16 , 17 ,
• Eugene V. McCloskey   ORCID: orcid.org/0000-0003-0177-8140 18 , 19 &
• Nicholas C. Harvey   ORCID: orcid.org/0000-0002-8194-2512 15 , 16  

12k Accesses

15 Citations

87 Altmetric

10 Mentions

Explore all metrics

Trabecular bone score (TBS) is a grey-level textural measurement acquired from dual-energy X-ray absorptiometry lumbar spine images and is a validated index of bone microarchitecture. In 2015, a Working Group of the European Society on Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) published a review of the TBS literature, concluding that TBS predicts hip and major osteoporotic fracture, at least partly independent of bone mineral density (BMD) and clinical risk factors. It was also concluded that TBS is potentially amenable to change as a result of pharmacological therapy. Further evidence on the utility of TBS has since accumulated in both primary and secondary osteoporosis, and the introduction of FRAX and BMD T-score adjustment for TBS has accelerated adoption. This position paper therefore presents a review of the updated scientific literature and provides expert consensus statements and corresponding operational guidelines for the use of TBS.

An Expert Working Group was convened by the ESCEO and a systematic review of the evidence undertaken, with defined search strategies for four key topics with respect to the potential use of TBS: (1) fracture prediction in men and women; (2) initiating and monitoring treatment in postmenopausal osteoporosis; (3) fracture prediction in secondary osteoporosis; and (4) treatment monitoring in secondary osteoporosis. Statements to guide the clinical use of TBS were derived from the review and graded by consensus using the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) approach.

A total of 96 articles were reviewed and included data on the use of TBS for fracture prediction in men and women, from over 20 countries. The updated evidence shows that TBS enhances fracture risk prediction in both primary and secondary osteoporosis, and can, when taken with BMD and clinical risk factors, inform treatment initiation and the choice of antiosteoporosis treatment. Evidence also indicates that TBS provides useful adjunctive information in monitoring treatment with long-term denosumab and anabolic agents. All expert consensus statements were voted as strongly recommended.

The addition of TBS assessment to FRAX and/or BMD enhances fracture risk prediction in primary and secondary osteoporosis, adding useful information for treatment decision-making and monitoring. The expert consensus statements provided in this paper can be used to guide the integration of TBS in clinical practice for the assessment and management of osteoporosis. An example of an operational approach is provided in the appendix.

This position paper presents an up-to-date review of the evidence base, synthesised through expert consensus statements, which informs the implementation of Trabecular Bone Score in clinical practice.

Similar content being viewed by others

The clinician’s guide to prevention and treatment of osteoporosis

M. S. LeBoff, S. L. Greenspan, … E. S. Siris

The 2023 Guidelines for the management and treatment of glucocorticoid-induced osteoporosis

Yoshiya Tanaka, Satoshi Soen, … Seiji Fukumoto

UK clinical guideline for the prevention and treatment of osteoporosis

Celia L. Gregson, David J. Armstrong, … Juliet Compston

Avoid common mistakes on your manuscript.

Introduction

Osteoporosis is conceptually defined as a systemic skeletal disease characterized by low bone mass and deterioration of bone microarchitecture, leading to bone fragility and a consequent increase in fracture risk [ 1 , 2 ]. This definition encompasses the two pillars of bone resilience to fracture: bone mass (the amount of bone present) and bone microarchitecture (the material and organizational properties of bone). The densitometric assessment of osteoporosis is based on a bone mineral density (BMD) T-score of − 2.5 or less, which captures the bone mass element of fracture risk and is effective in identifying some, but not all individuals who go on to experience a fragility fracture [ 3 , 5 , 6 ]. An important clinical challenge is that most fragility fractures occur in individuals who have a BMD T-score in the osteopenic or normal range and therefore fall below the originally defined densitometric interventional threshold [ 3 , 4 , 5 , 6 ]. Ideally, the skeletal assessment of bone fragility should also capture bone microarchitecture as the second pillar of fracture resilience in order to improve the identification of individuals at high risk of fracture.

Trabecular bone score (TBS) is a grey-level textural measurement usually acquired from conventional lumbar spine dual-energy X-ray absorptiometry (DXA) BMD images, which provides a validated index of bone microarchitecture and correlates with mechanical properties of bone [ 7 , 8 , 9 , 10 , 11 , 12 ]. The score may be used as a continuous variable, by adjusting FRAX probability or BMD T-score, and has been interpreted clinically with cut-off values at thirds of the distribution [ 13 , 14 ]. In 2015, a review of the evidence for TBS in the assessment of osteoporosis was conducted by an Expert Working Group of the European Society on Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) [ 15 ]. The review concluded that TBS predicts hip and major osteoporotic fracture risk, at least partly independent of BMD and clinical risk factors and that TBS is potentially amenable to change as a result of pharmacological therapy [ 15 ]. Since then, the evidence base has rapidly expanded, with advances in the understanding of the role of TBS for fracture risk assessment in secondary as well as primary osteoporosis, for example in type 2 diabetes [ 16 , 17 , 18 ]. Evidence has also accumulated on the added value of TBS for decisions on treatment initiation and in understanding the effects of different antiosteoporosis therapies on bone microarchitecture in conjunction with known mechanisms of action [ 19 , 20 , 21 , 22 , 23 , 24 ]. It is estimated that over 2 million TBS assessments are performed annually (data extrapolated from Kanis et al., 2021) [ 25 ], with the clinical interpretation of results supported by FRAX® [ 13 , 26 ] and BMD T-score adjustments for TBS [ 14 ]. Given this rapid expansion of the scientific literature and the increasing clinical adoption of TBS, the ESCEO and International Osteoporosis Foundation (IOF) convened a Working Group to review the updated evidence base and provide guidance on the integration of TBS into clinical practice. The Appendix presents practical suggestions relating to clinical implementation and technical issues, derived from the Expert Working Group statements, technical information and clinical experience.

The international Expert Working Group included independent clinical scientists, physicians and researchers with expertise in the assessment, diagnosis and treatment of osteoporosis. Prior to the Working Group meeting, four topics were selected for review and systematic reviews of the evidence were undertaken: (1) use of TBS in fracture risk prediction; (2) use of TBS for treatment initiation and assessing response to pharmacological interventions in postmenopausal osteoporosis; (3) use of TBS for the assessment of fracture risk in secondary osteoporosis; and (4) use of TBS for assessing response to pharmacological therapies in secondary osteoporosis.

Systematic review search strategy

A comprehensive literature search was conducted using a similar approach to PRISMA guidelines, for articles published in MedLine via PubMed [ 27 ]. Fracture syntax (topics 1 and 3, Fig.  1 a) comprised ‘trabecular bone score’ OR ‘TBS’ [search term(Title/Abstract)], AND ‘fracture(s)’ [search term(Title/Abstract)]. Treatment syntax (topics 2 and 4, Fig.  1 b) comprised ‘trabecular bone score’ OR ‘TBS’ [search term(Title/Abstract)], AND ‘treatment(s)’ AND ‘effect’ [search term(Title/Abstract)], OR ‘therapy(ies)’ [search term(Title/Abstract)], OR ‘trial’ [search term(Title/Abstract)] AND ‘effect’ [search term(Title/Abstract)]. Articles were considered for review if they met the following general screening criteria: (i) an original, full-text study with TBS as a primary outcome, (ii) published or in-press (or known ‘accepted’ status and shared by a co-author) between March 2015 and 9 th February 2023, and (iii) available in the English language. Further eligibility criteria were specific to each of the four topics. A total of 96 papers were reviewed by 2 independent reviewers.

A PRISMA flow diagram of the literature search process for studies investigating trabecular bone score (TBS) and fracture prediction in primary and secondary osteoporosis. b PRISMA flow diagram of the literature search process for studies investigating trabecular bone score and treatment monitoring in postmenopausal and secondary osteoporosis

Expert consensus statements and operational guidelines

Expert consensus statements were developed in accordance with the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) approach [ 28 ]. The GRADE approach is a widely used method for evaluating the quality of evidence and developing clinical recommendations. It provides a systematic and transparent process for assessing the certainty of the evidence, balancing the benefits and harms of interventions, and formulating recommendations. The GRADE approach involved several key steps:

Identifying the clinical questions: The first step involved defining the clinical questions regarding TBS, that the recommendations were to address. This included specifying the population and outcomes of interest.

Assessing the quality of evidence: the quality of evidence for each outcome was assessed using a systematic approach, with a defined study eligibility criteria, and considering methodological factors.

Rating the certainty of evidence: the certainty of evidence was characterized according to four levels: good, moderate, low, or very low. This rating reflects the confidence that the evidence accurately represented the true effect of TBS on a given outcome.

Formulating recommendations: a consensus process was followed to develop recommendations. The International Working Group, consisting of experts in the field, considered the quality and certainty of the evidence, the balance between benefits and harms, clinical experience, practical and resource implications, and other relevant factors.

Grading the strength of recommendations: a level of strength was assigned to each recommendation, indicating the extent to which the Working Group believes the benefits of the intervention outweigh the potential harms. Recommendations could be classified as either strong or weak.

The primary purpose of the GRADE approach is to help clinicians, researchers, and guideline developers make informed decisions based on the available evidence while considering various factors that may influence clinical practice. The process included a face-to-face meeting of the Working Group on 9 th February 2023 with presentations on each topic. Following the GRADE approach and based on the discussions and review outcomes, 22 corresponding statements were developed to inform guidance on the use of TBS in clinical practice. Thereafter, operational guidance to support the integration of TBS in clinical practice was developed.

Topic 1: Use of TBS in fracture risk prediction in postmenopausal and male osteoporosis

Eighteen studies met the eligibility criteria (prospective study design, conducted in men and/or women aged 40 years or over; Fig.  1 a). Of these, one study was conducted in Australia [ 29 ], five in Canada [ 14 , 30 , 31 , 32 , 33 ], two in China [ 34 , 35 ], two in Japan [ 36 , 37 ], one in Korea [ 38 ], one in Slovakia [ 39 ], three in Switzerland [ 40 , 41 , 42 ], one in Thailand [ 43 ], and two in the USA [ 44 , 45 ]. Cohort sizes from different ethnicities ranged from 115 to 45,185, and follow-up from 2.7 to 10 years. Ten studies were conducted in postmenopausal women, five in men, and three in both men and women, with mean age ranging from 58 to 76 years. The incident fracture rates for major osteoporotic fractures (MOF, including hip) ranged from 1.2 to 14%, and for vertebral fractures, 3.5 to 35% (Table 1 ). TBS was an independent predictor of incident fracture in 16 of 18 studies (Table 1 ). For each SD reduction in TBS, the increased risk of incident fracture ranged from 19% [ 14 ] to more than double [ 39 , 40 ]. The combination of TBS and BMD significantly enhanced the prediction of fracture risk compared to lumbar spine BMD in men and women [ 27 , 40 , 41 , 42 , 44 ], although, in one study, this was only significant in men [ 34 ].

TBS-adjusted FRAX

In 2016, a meta-analysis of 14 prospective population cohort studies showed that TBS is a significant predictor of fracture risk independent of FRAX and that the adjustment of FRAX for TBS resulted in a small but significant increase in fracture risk prediction, independent of gender and ethnicity [ 13 ]. The impact of TBS adjustment on FRAX probabilities is dependent on age, femoral neck BMD and the FRAX probability value [ 46 ]. Since 2016, four further prospective studies in women [ 14 , 30 , 37 , 41 ] and three in men [ 35 , 36 , 44 ] have since demonstrated that TBS combined with FRAX enhances the prediction of MOF, hip and vertebral fracture, compared with FRAX alone. Used together, the global assessment of fracture risk considers bone mass, bone microarchitecture and clinical risk factors (CRF). One recent study examined whether antiresorptive treatment affects fracture risk prediction from TBS using a large clinical registry ( n  = 76,810) that includes all DXA tests for the Province of Manitoba, Canada. Results showed that TBS was a robust predictor of fracture in models adjusted for clinical risk factors and BMD and that the use of antiresorptive treatment (mostly bisphosphonates) either in the year before or following TBS measurement (mean total use, 5.6 years) did not attenuate fracture risk prediction [ 33 ].

Over a 10-year follow-up period in 1541 Japanese women (mean age 58 y) [ 37 ], every SD increase in TBS-adjusted FRAX score equated to a 46% increased risk of fracture (OR: 1.46, 95%CI 1.08, 1.98) compared to 35% with FRAX alone (OR: 1.35, 95%CI 1.09, 1.67). Similar results were found in the Fujiwara-Kyo Osteoporosis Risk in Men (FORMEN) study [ 36 ], and in Chinese men from the MrOs. Hong Kong cohort [ 35 ]. In the latter, when applying the Taiwan Intervention Strategy treatment threshold of 12.5% [ 47 ], TBS-adjusted FRAX improved the net risk classification by 5.2% compared to FRAX without TBS [ 35 ]. These findings are consistent with those in Caucasian men and women [ 44 , 48 , 49 ].

In 5863 men (mean age 73.7 y) from the MrOS cohort, over 8.6 years [ 44 ], TBS significantly predicted incident MOF and hip fracture, independent of FRAX with BMD, and prevalent radiographic vertebral fracture. For each SD reduction in TBS, there was a 27% (HR: 1.27, 95%CI 1.17, 1.39) and 20% (HR: 1.20, 95%CI 1.05, 1.39) greater risk of MOF and hip fracture, respectively. Using the 20% National Osteoporosis Foundation (NOF, now the Bone Health Osteoporosis Foundation, BHOF) treatment threshold, [ 50 ] the addition of TBS to FRAX also increased the Net Reclassification Index (NRI) by 3.3%, and with TBS, FRAX and prevalent radiographic vertebral fracture, the NRI increased further to 6.2%.

Similar results were found in 34,316 women from the Manitoba cohort (mean age 63.5 y), over 8.7 years [ 30 ]. The NRI with TBS-adjusted FRAX was computed using treatment thresholds from three clinical guidelines: Bone Health and Osteoporosis Foundation (BHOF) [ 50 ], Osteoporosis Canada [ 51 ] and the UK National Osteoporosis Guideline Group [ 52 ]. For all thresholds, the TBS adjustment had a positive effect in identifying fracture cases. In the overall group, TBS-adjusted FRAX yielded a small but significant increase in the NRI (NRI = 3.5% p  = 0.002) compared with FRAX alone. Most reclassification occurred in individuals with a non-osteoporotic T-score (NRI = 3%), and there was also an age interaction, with reclassification more frequent in women under 65 years of age (NRI = 5.6%, p  < 0.001). Consistent with findings elsewhere reporting up to 25% reclassification [ 14 , 48 , 49 , 53 ] and as expected, most reclassification (> 90%) occurred for women close to an intervention cut-off (range 9 to 17.9%), suggesting that the clinical utility of TBS (i.e. altering risk classification and hence intervention decisions) is particularly enhanced when targeted to this segment of the population.

TBS-adjusted BMD T-score

The adjustment of BMD T-score for TBS represents a clinically relevant advancement in the field, deriving from the analysis of the Manitoba cohort of 45,185 women (mean age 63.5 y) on GE DXA systems [ 14 ] and confirmed in the OsteoLaus cohort using a Hologic DXA system [ 54 ]. In the Manitoba cohort at follow-up (mean 7.4 y), 3925 of women (8.7%) had sustained at least one incident MOF, and 1040 (2.3%) had sustained at least one incident hip fracture [ 14 ]. Each SD decrease in TBS was significantly associated with a 26%, 25% and 22% greater risk of MOF in models incorporating BMD at the lumbar spine, femoral neck and total hip, respectively, and the results were not attenuated after adjustment for age and BMI. Using risk estimates from the Cox proportional hazards models, the authors applied a risk-equivalent offset adjustment to BMD T-scores to derive TBS-adjusted BMD T-scores for each site (spine, neck and total hip). There were significant improvements in fracture risk prediction using the TBS-adjusted BMD T-scores, compared to the unadjusted T-scores. Of relevance when FRAX is the primary approach, the study also confirmed the strong agreement in fracture probability scores between the TBS-adjusted FRAX tool, and when using TBS-adjusted femoral neck BMD T-score as the BMD input to FRAX ( r 2  = 0.98, slope = 1.02, intercept =  − 0.3).

The combination of TBS with BMD for fracture prediction has been examined in the Swiss Evaluation of Methods of Measurement of Osteoporotic Fracture Risk (SEMOF) cohort study of 556 older women (mean age 76.1 y). Here, TBS significantly predicted incident fracture, independent of BMD (HR = 2.01, 95%CI 1.54, 2.63) [ 40 ]. The combination of TBS with lumbar spine BMD or the lowest BMD, significantly enhanced fracture prediction, with significantly different areas under the receiver operator curve (AUC) compared to models without TBS. Compared to osteoporosis (58%) or degraded TBS (60%) alone, the combination of osteoporosis and degraded TBS improved the classification of women with an osteoporotic fracture to 77%, confirming findings elsewhere in postmenopausal women [ 55 ] and non-osteoporotic patients [ 56 ]. Degraded TBS was categorized using data from a meta-analysis [ 13 ], where L1 to L4 TBS risk thresholds were established using a gender-independent tertile approach, with cut-off values for TBS of 1.23 and 1.31. Those with TBS values above 1.31 were characterised as being at low risk of fracture, those between 1.31 and 1.23 at intermediate risk and, finally, those below 1.23 at high risk of fracture. In subsequent studies, and in clinical usage, these tertiles have been termed normal TBS, partially degraded TBS and degraded TBS respectively.

Overall, whilst FRAX is widely available, and indeed is incorporated into over 100 guidelines internationally, some national guidelines predicate treatment on the basis of T-score rather than absolute fracture probability [ 57 ]. Furthermore, FRAX models are not available for all countries or territories. In these settings, the use of TBS-adjusted BMD T-score provides a practical method in which TBS information can be incorporated into risk assessment approaches.

Statements (GRADE outcome: strongly recommended)

The expert Working Group made the overall recommendation that TBS should be used in conjunction with BMD and clinical risk factors. Individual statements, all of which were strongly supported by the members of the Working Group, are itemized below:

TBS is predictive of fragility fractures in postmenopausal women and men above the age of 50 years.

TBS is predictive of fragility fractures independent of BMD and of clinical risk factors (including those in FRAX).

TBS adds predictive value when used in association with FRAX and BMD to adjust the FRAX probability of fracture in postmenopausal women and in men above the age of 50 years.

BMD adjusted for TBS is an alternative solution when FRAX is not available.

The greatest utility of TBS is for those individuals who lie close to a FRAX or BMD T-score intervention threshold.

TBS continues to add value to FRAX in patients previously receiving antiresorptive treatments.

Topic 2: Use of TBS for the initiation of treatment and monitoring of treatment effect in postmenopausal osteoporosis

Twenty studies met the eligibility criteria (prospective or intervention trial of an antiosteoporosis treatment in postmenopausal women, ≥ 6 months treatment duration; Fig.  1 b), and six were international multi-centre trials. Of those remaining, two were conducted in Canada, two in Japan, two in India, four in South Korea, one in Spain, one in Taiwan and two in the USA. Cohort sizes ranged from 28 to 6985 and treatment duration, from 6 months to 10 years. Studies included antiresorptive treatments anabolic treatments, and/or sequential treatment and/or treatment combinations (Table 2 ).

Antiresorptive agents

Antiresorptive treatment studies included bisphosphonates, menopausal hormone therapy (MHT), selective estrogen receptor modulators (SERMs) and denosumab (Table 3 ), which act in different ways to inhibit osteoclast activity [ 72 ], maintaining trabecular structure and increasing bone mass. Bisphosphonate treatment duration ranged from 12 to 49 months. Seven studies reported a preservation of TBS with bisphosphonates, SERMs and MHT [ 19 , 22 , 23 , 57 , 60 , 62 , 63 ] and three reported small, significant gains ranging from 0.7 to 1.4% over 12 months [ 57 , 59 , 71 ]. Seven reported significant gains in BMD, ranging from 1.5 to 4.9% over 12 months [ 19 , 22 , 57 , 59 , 60 , 62 , 63 ].

One recent study examined changes based on least significant change (LSC) in 6,985 adults (mean age 65 y, 94% women) treated primarily with bisphosphonates (78.3%), followed by SERMs (12%) then MHT (6.2%), over a mean treatment period of 38 months [ 69 ]. Consistent with findings from studies reporting on group mean treatment effects [ 18 , 22 , 57 , 59 , 60 , 61 , 62 ], the proportion of individuals with an increase in lumbar spine BMD (22%) and hip BMD (17.6%) was greater than those who had an increase in TBS (9.3%). The treatment effect on TBS was primarily one of preservation which aligns with the mechanisms of action (TBS: 76.9% within LSC, Table 2 ) [ 69 , 72 ]; indeed an increase in TBS would not necessarily be expected with antiresorptive treatment. An increase in TBS greater than the LSC should occasion consideration of potential technical factors, such as change in body weight, tissue thickness or scan mode, all of which also impact changes in BMD though to a somewhat lesser extent [ 69 ]. It is noteworthy that in the same study, 24.9% and 16.1% of patients had a decrease in hip and spine BMD which exceed LSC, which might also necessitate an investigation of clinical issues such as compliance or technical issues such as scan mode, weight change and DXA instrument.

Denosumab treatment durations ranged from 20 months to 10 years (Table 3 ). All studies reported significant increases in TBS with denosumab treatment, ranging from 0.4 to 1.8% /12 months, and increases in BMD ranging from 1.9 to 6%/12 months. One study included a comparison of TBS software versions for monitoring treatment with denosumab over 36 months [ 70 ]. Denosumab led to progressive increases in BMD and TBS over 36 months, with both TBS (version 3, BMI-adjusted) and TBS (version 4.0, tissue thickness adjusted) changes being significant compared to baseline and compared to placebo, from months 12 to 36 ( p  < 0.001). The mean percent changes from baseline with TBS version 3.0 were 1.4%, 1.5% and 1.9%, at months 12, 24, and 36 respectively, while for TBS (version 4.0), the mean increases were slightly better at 2.3%, 2.6% and 3.3%, respectively [ 70 ]. In a further study, the efficacy of long-term denosumab therapy was investigated in 279 postmenopausal women who were randomized to either long-term denosumab treatment for 10 years or placebo for 36 months followed by denosumab for 7 years [ 24 ]. Consistent increases in TBS to 4.7% and in BMD to 22.4% were observed in women on long-term denosumab treatment. For women in the cross-over denosumab group, there were significant increases in TBS to 3.2% for seven years following treatment initiation, and in BMD, to 17.2%. At the individual level, denosumab treatment over 10 years resulted in a reduction in the proportion of women with degraded TBS (from 48.6 to 29.1%) and an increase in the proportion of women with normal TBS (26.1 to 53.2%). Similarly, there was a reduction in the proportion of women classified at high risk of fracture according to the combination of TBS and BMD T-score (from 94 to 40%) [ 24 ]. Furthermore, consistent with TBS as a predictor of fracture, women with the greatest improvements in TBS experienced fewer new fractures or worsening fractures across the trial duration [ 24 ].

Collectively, the evidence indicates that bisphosphonates, SERMs and MHT are unlikely to result in TBS change as they act primarily to preserve bone microarchitecture, as confirmed by histomorphometric analyses [ 72 , 73 ]. On the other hand, denosumab, a more potent antiresorptive agent [ 72 , 74 ] with a potential bone-forming effect [ 74 ], results in sustained, modest to large gains in TBS with extended treatment durations up to 10 years [ 24 ].

Anabolic agents

Anabolic treatments studied included parathyroid hormone (PTH) analogues which act by increasing bone formation and resorption, and romosozumab, which through a novel, dual mode of action, rapidly increases bone formation and reduces bone resorption [ 75 ]. In histomorphometric analyses, both classes of treatment have been shown to significantly improve trabecular microarchitecture and bone volume [ 76 , 77 ]. Eight studies included PTH/PTHrP analogues (teriparatide and/or abaloparatide) and demonstrated mean increases in TBS from 1.3 to 4.8%/12 months and increases in BMD ranged from 2.0 to 8.3%/12 months (Table 2 ).

In a multi-national randomized controlled trial (RCT), 109 postmenopausal women (mean age 61.5 y) received abaloparatide (20, 60 or 80ug) or 20 ug teriparatide over 6 months [ 66 ]. Rapid increases in TBS were observed in all treatment groups, with the greatest increases observed with the higher 80ug dose of abaloparatide (4.2%). At the individual level, 52% of women on abaloparatide (80ug) and 30% of women on teriparatide, had a TBS increase which exceeded LSC. With a longer intervention duration, the ACTIVE and ACTIVExtend RCT demonstrated a mean TBS increase of 4% over 18 months in 457 postmenopausal women treated with abaloparatide [ 23 ]. This increase was sustained to 4.4% at 43 months, and 50% of women had a positive change which exceeded LSC. There was also a reduction in the proportion of women with degraded TBS (from 40 to 24%) while there was no change in the TBS category for women in the placebo group (from 43 to 45%). In the same trial, compared to those not having an increase in TBS greater than LSC (3.8%), the odds ratio of sustaining a new vertebral fracture over 43 months was lower in those with a greater than LSC increase at 6 months (OR: 0.19, 95%CI 0.04, 0.8) and at 43 months (OR: 0.3, 95% CI 0.11,0.79) [ 23 ].

Romosozumab rapidly increased lumbar spine and hip BMD with an effect size greater than that observed with PTH/PTHrP analogues [ 76 ]. Treatment with romosozumab results in significant reductions in vertebral fracture and MOF risk [ 77 ] and medication has been recommended as the first line of treatment in patients with very high fracture risk [ 78 , 79 ]. Two studies have investigated the effect of romosozumab on TBS [ 22 , 71 ]. The first, in a small sample of 10 women (mean age 66 y), demonstrated a 2.5% mean increase in TBS and an 8.3% increase in lumbar spine BMD with 6 months of romosozumab treatment [ 22 ]. Conversely, in this study, there were no changes in TBS following 12 months of antiresorptive treatment [ 22 ]. In the ARCH multi-centre RCT, TBS measurements were available in 378 women (mean age 73 y, ~ 9.3% of the study population) randomized to receive either romozosumab or alendronate [ 71 ]. Over 12 months, mean TBS increased significantly by 5.1% in women treated with romosozumab, compared to no significant change (mean + 1.5%) in those treated with alendronate [ 69 ]. Furthermore, treatment with romosozumab led to a reduction in the proportion of women with degraded TBS (from 52.6 to 33%) and an increase in the proportion of women with normal TBS (28.9 to 48.1%). In women treated with alendronate only, there was a smaller reduction in the proportion of those with degraded TBS (from 60.6 to 51.6%) and a smaller increase in those with normal TBS (from 26.1 to 33%) [ 71 ].

Sequential osteoporosis treatment regimens

The long-term management of osteoporosis, particularly in patients at very high fracture risk, may necessitate sequential treatment [ 79 ]. Recent recommendations suggest that this may require an anabolic-first treatment regimen with a bone-forming agent (such as romosozumab or PTH, PTH/PTHrP-analogue) for 1–2 years, followed by an antiresorptive (such as a bisphosphonate or denosumab) for a further 5–10 years [ 80 ]. In the DATA-Switch open-label trial, postmenopausal women were allocated to sequential treatment comprising teriparatide to denosumab, or denosumab to teriparatide [ 21 ]. After 24 months, TBS gains were greater in the anabolic first group (2.7% versus 1.8%), and continued to increase for a further 24 months, following the treatment switch (5.1% versus 3.6%). In the ARCH multi-center trial, the 5.1% increase in TBS with romosozumab at 12 months was maintained to 4.8% with alendronate, for a further 24 months [ 71 ]. In a comparison group of women treated only with alendronate, gains in TBS were lower (1.5% at 12 months, 2.5% at 36 months). This approach may also be useful in patients whose very high risk of fracture is driven by reduced bone density and/or degraded bone microarchitecture.

TBS and treatment decision-making

The initiation of treatment is increasingly driven by fracture risk, which may be assessed by a variety of risk assessment modalities, depending on the availability of densitometry and FRAX, and on country or regional-specific guidance. European guidelines recommend FRAX-based approaches [ 81 , 82 ] with age-dependent intervention thresholds [ 83 ]. The adjustment of FRAX for TBS provides a global risk assessment based on bone mass and bone microarchitecture, plus clinical risk factors. Alternatively, the adjustment of the lowest BMD for TBS captures fracture risk associated with reduced bone mass and degraded bone microarchitecture, and the adjusted T-score may be entered into fracture risk calculators, such as the Garvan fracture risk calculator [ 84 ]. At the conceptual level, the information that TBS conveys regarding bone microarchitecture suggests that this measure, taken with BMD and CRFs, might contribute to decisions about specific treatment strategies. For example, on this basis, a treatment regimen might be chosen to either increase BMD and preserve bone microarchitecture, or to increase both BMD and bone microarchitecture, with consolidation thereafter. While a conceptually appealing mechanism by which treatment could be chosen according to individual patient characteristics, it clearly requires further evidential underpinning in order to properly inform this suggested approach.

As with BMD, the monitoring of treatment effect at the individual level should apply LSC based on centre-specific precision error and acquired in accordance with ISCD guidelines [ 85 ]. Few studies to date have reported on the proportion of study participants exceeding TBS or BMD LSC [ 19 , 20 , 23 , 66 ], and it is recommended that future studies include this data to enable interpretation of treatment effect at the individual level. Precision errors for TBS using Hologic or GE DXA systems and different TBS software versions, are comparable to BMD precision [ 84 ] and have ranged from 0.8 to 2.1%CV with equivalent LSC ranging from 2.2 to 5.8%. The average precision error and LSC from studies to date are 1.4%CV and 3.8% respectively [ 9 , 36 , 40 , 63 , 68 , 86 , 87 , 88 , 89 , 90 , 91 ]. The corresponding LSC unit change in TBS has been reported to be 0.05 based on a precision of 1.4%CV [ 85 ].

The expert Working Group members made the general recommendation that TBS results should be interpreted within the clinical context of the patient. Individual statements, all of which were strongly supported by the members of the Working Group, are itemized below:

Patients with low TBS who lie below but near the treatment threshold should be considered for an earlier assessment and lifestyle advice.

TBS with BMD and FRAX probability contributes to the stratification of antiosteoporosis therapy according to fracture risk, directing very high-risk patients to anabolic-first approaches.

TBS in conjunction with BMD, is useful for monitoring individual response to long-term denosumab treatment (5 years or more).

TBS in conjunction with BMD is useful for monitoring individual response to PTH/PTHrP-analogue treatments such as teriparatide and abaloparatide.

TBS in conjunction with BMD is useful for monitoring the individual response to romosozumab.

A decrease in TBS more than LSC during treatment should prompt further clinical review.

TBS contributes useful information in the assessment of treatment response for patients receiving bone-forming agents or long-term denosumab.

Topic 3: Use of TBS in the prediction of fracture risk associated with secondary osteoporosis

Consistent with the growing clinical and research interest in this area, in 2015, four studies with fracture outcomes in secondary osteoporosis were reviewed [ 15 ], whereas, in the current review, 40 studies (seven prospective) met the eligibility criteria (prospective, retrospective or cross-sectional studies, fracture as the primary outcome, in men and/or women aged ≥ 18 years). Of these, three were conducted in Australia, one in Brazil, four in Canada, sixteen in Europe, two in India, three in Japan, four in South East Asia, seven in South Korea; 27 studies included men and 36 included women. Incident fragility fracture rates ranged from 8 to 31% and for prevalent fracture, from 10 to 45% (Table Sb, supplementary information). As would be expected, studies were often smaller, and more frequently cross-sectional rather than prospective, compared with those of TBS in the context of primary osteoporosis and risk assessment.

Type 2 diabetes

Type 2 diabetes (T2D) is associated with an increased risk of bone fragility and fractures, although the underlying mechanisms are not fully understood. Individuals with T2D have a higher risk of fractures despite in some cases, having higher BMD than non-diabetic individuals. This paradoxical relationship between BMD and fracture risk suggests that other factors, such as impaired bone quality (for example greater heterogeneity of trabecular bone microarchitecture and increased cortical porosity) and altered material properties (as a consequence of protein glycation), may be implicated [ 92 , 93 , 94 , 95 ]. Indeed, previous studies have suggested that the altered trabecular microarchitecture is at least in part due to the accumulation of advanced glycation end products in bone tissue which increases the propensity to fracture [ 96 , 97 ]. Accordingly, the risk appears to be greater in patients who have poorer glycemic control [ 94 , 95 , 98 ]. In the current review, eight studies with cohort sizes between 169 and 44,503, investigated the use of TBS for the prediction of fragility fracture in T2D patients (Table Sb, supplementary information). In seven studies, TBS was related to fragility fracture risk independent of BMD [ 16 , 17 , 18 , 99 , 100 , 101 , 103 ] and three reported enhanced fracture risk prediction with TBS-adjusted FRAX compared to FRAX alone [ 16 , 99 , 100 ]. In 44,543 men and women (mean age 63.9 y) from the Manitoba cohort, 3,946 (9%) sustained an incident MOF over a mean follow-up of 8.3 years [ 99 ]. Individuals with T2D ( n  = 4136) had significantly lower TBS but higher femoral neck BMD ( p  < 0.05). Diabetes was also a significant predictor of incident fragility fracture risk, supporting findings from earlier studies in both sexes [ 94 , 95 ] and of microarchitectural deterioration in T2D-related skeletal fragility [ 100 ]. The adjustment of FRAX for TBS in the diabetes sub-group resulted in an overall NRI of 3.9% for incident MOF and 2.5% for hip fracture. Most reclassification was upward, based on a fixed intervention threshold of 20% for MOF and 3% for hip fracture [ 100 ].

Hypercortisolism and glucocorticoid-induced fracture risk

Six cross-sectional studies examined associations between TBS and prevalent or recent fragility fracture in patients with Cushing’s syndrome [ 104 ] or treated with corticosteroids [ 105 , 106 , 107 , 108 , 109 ]. All reported that TBS was associated with fracture, independent of BMD. In 182 men and women with Cushing’s syndrome (mean age 37.8 y; 45% fractured), there were no associations between BMD and fracture [ 104 ]. However, 84% of fractured patients had either degraded (50%) or partially degraded (34%) TBS (compared to 40% with low BMD), suggesting an important role for TBS-detected parameters including degraded trabecular architecture in the elevated fracture risk associated with endogenous overproduction of cortisol [ 104 ]. Comparable skeletal profiles have also been observed in patients receiving long-term corticosteroid treatment [ 108 , 109 ]. In 127 Spanish patients treated with corticosteroids (mean duration, 47.7 months), 27% had sustained a recent fragility fracture [ 108 ]. The skeletal profiles of patients with vertebral or non-vertebral fragility fracture were predominantly characterized by degraded TBS (76% and 69% respectively) rather than densitometric osteoporosis (38% and 36% respectively).

Chronic kidney disease

Seven studies met the inclusion criteria and investigated the use of TBS for predicting fracture in patients with chronic kidney disease (CKD) [ 110 , 111 , 112 , 113 , 114 , 115 , 116 ]. Five studies showed that TBS predicted incidents or were associated with a prevalent fragility fracture, independent of BMD [ 110 , 111 , 112 , 113 , 114 ]. Whilst CKD metabolic bone disease represents several different histomorphometric phenotypes, the search did not identify studies specifically addressing this point. In 1426 men and women (mean age 67 y), reduced kidney function was associated with significantly lower TBS and a higher probability of fracture (18% vs. 6%, p  = 0.01) and low TBS predicted greater incidence of fragility fractures over 4.7 years, independent of BMD and CRFs [ 110 ]. Lower TBS also corresponds with increasing disease severity [ 111 , 112 ]. In hemodialysis patients (mean age 74 y), TBS and not BMD, was a significant, independent predictor of fracture [ 115 ]. Two studies did not report an association between TBS and fracture risk in CKD patients. First, a retrospective cohort study, found that neither TBS nor BMD were related to a history of fracture in men with moderate CKD (age 33 to 96 y) [ 113 ]. Second, in a prospective study of a modest sample of 59 CKD patients (mean age 68 y), FRAX-adjusted for TBS was higher in fracture compared to non-fracture cases (16.8% versus 10.6%), but the predictive model did not reach statistical significance [ 112 ].

Rheumatological conditions

Ten studies investigated TBS for fracture prediction/discrimination in rheumatological inflammatory conditions including rheumatoid arthritis [ 118 , 119 , 120 ], axial spondyloarthritis [ 121 ], ankylosing spondylitis [ 122 , 123 , 124 ], polymyalgia rheumatica [ 125 ], systemic lupus erythematosus [ 126 ] and systemic sclerosis [ 127 ]. The risk factors for skeletal fragility in these conditions include inflammatory disease mechanisms and cytokine-activation of bone resorption, in addition to the use of glucocorticoid and other immunosuppressive drugs, which are known to affect bone microarchitecture [ 128 ]. All studies showed that TBS was significantly associated with fracture, independent of BMD. In two studies of postmenopausal women with rheumatoid arthritis, TBS but not BMD was associated with a prevalent radiographic vertebral fracture [ 118 , 119 ], and adjustment of FRAX for TBS improved fracture risk prediction compared to FRAX alone [ 119 ]. In a separate study of 142 rheumatoid arthritis patients and 106 healthy controls, lower TBS was associated with vertebral fracture and of those with vertebral fracture, 26% had normal lumbar spine BMD and 12% had normal hip BMD [ 120 ].

Axial spondyloarthritis and ankylosing spondylitis are chronic inflammatory conditions that can lead to structural damage to bone tissue, degraded bone microarchitecture and increased fracture risk [ 129 ]. In all four studies reviewed, TBS was significantly associated with past or incident fracture [ 121 , 122 , 123 , 124 ], and in two studies femoral neck BMD, but not lumbar spine BMD, was lower in fracture cases [ 122 , 124 ]. In patients with axial spondylitis, those with fractures were more likely to have degraded TBS (29%) than low BMD (14%) [ 121 ]. It is also important to consider that lumbar spine BMD can be falsely elevated in degenerative noninflammatory arthropathy (due to sclerosis and osteophytes) and in certain inflammatory rheumatic diseases including ankylosing spondylitis (resulting from syndesmophyte formation). In a recent study of 63 spinal surgery patients, lumbar spine BMD was significantly increased with higher CT-derived degeneration scores ( p  < 0.001) whereas TBS and CT Hounsfield unit measurements were unaffected [ 130 ]. In the case of a patient who may have degraded TBS and normal or increased lumbar spine BMD, careful scrutiny of the DXA image is recommended to ensure that no vertebrae are affected by spinal artefacts.

Other causes of secondary osteoporosis

Ten studies investigated other causes of secondary osteoporosis including acromegaly, cirrhosis, hyperparathyroidism, pulmonary disease, HIV infection, and thalassemia [ 131 , 132 , 133 , 134 , 135 , 136 , 137 , 138 , 139 , 140 ]. These studies tended to be small and cross-sectional in nature. In one study of 106 men and women with acromegaly (mean age 56 y), despite lower TBS in vertebral fracture cases (1.18 vs. 1.202, p  < 0.05), TBS was not associated with prevalent vertebral fractures in a multivariate model [ 134 ]. In the other nine studies, TBS was associated with prevalent vertebral fractures, independent of BMD [ 131 , 132 , 133 , 135 , 137 , 138 , 139 , 140 ] or enhanced fracture prediction when combined with BMD [ 136 ]. In four of these studies, however, BMD did not differ between fracture and non-fracture cases [ 131 , 133 , 135 , 139 ].

Five studies examined TBS and hyperparathyroidism or hypoparathyroidism; conditions which are known to lead to alterations to trabecular bone microarchitecture [ 141 , 142 ]. In studies of patients with hyperparathyroidism or hypoparathyroidism, TBS was significantly lower in fracture compared to non-fracture cases [ 132 , 135 , 137 , 139 , 140 ]. In studies that examined the skeletal profiles of fracture cases, the prevalence of degraded TBS (35 to 57%) was greater than densitometric osteopenia or osteoporosis (11 to 21%) [ 137 , 139 ]. Similar skeletal profiles indicating a predominance of altered bone microarchitecture were also reported in chronic obstructive pulmonary disease [ 135 ] and thalassemia [ 136 ]. In patients with thalassemia, more fractured patients had degraded TBS (57%) than low BMD (20%) [ 136 ].

Reductions in TBS are observed in most secondary osteoporosis-related diseases.

TBS predicts fracture risk in type 2 diabetes, independently of BMD and FRAX probability.

TBS predicts fracture risk in chronic kidney disease, independently of BMD.

TBS predicts fracture risk in patients treated with glucocorticoid, independently of BMD.

TBS predicts fracture risk in rheumatological diseases, for example, rheumatoid arthritis, independently of BMD.

TBS is relatively unaffected by spinal changes such as osteophytes and syndesmophytes.

Topic 4: Use of TBS for treatment monitoring in secondary osteoporosis

Twenty-eight studies met the eligibility criteria (prospective, retrospective cohort or case–control cross-sectional design; treatments associated with secondary causes of osteoporosis, or antiosteoporosis therapies in secondary osteoporosis; men and/or women, age ≥ 18 years) and thirteen studies included men (Table 3 ). One study was conducted in China, one in Denmark, one in France, four in Italy, two in Japan, five in Korea, one in Norway, one in Poland, one in Slovakia, two in Spain, two in Switzerland, one in Taiwan and six in the USA. Fourteen studies investigated the effects of treatments associated with secondary osteoporosis, and fourteen investigated the efficacy of antiosteoporosis therapies (Table 3 ).

Aromatase inhibitors

Aromatase inhibitors (AI) are first-line therapies for reducing the risk of cancer recurrence in postmenopausal women with hormone-receptor-positive breast cancer, by inhibiting the conversion of androgens to estrogen. Given this mechanism of action, AI therapies accelerate bone turnover, increase bone resorption, reduce bone density and increase fragility fracture risk [ 143 ]. Four studies investigated the effect of AI therapy (duration from 18 to 48 months) on TBS in postmenopausal or early postmenopausal women with breast cancer [ 144 , 145 , 146 , 147 ]. Reductions in TBS ranged from − 0.5 to − 1.5%/12 months, with the greatest loss observed over 36 months (− 4.6%), unrelated to change in BMD [ 145 ]. In a retrospective, longitudinal study of 321 non-osteoporotic postmenopausal women with breast cancer (mean age 59 y), AI treatment for 3 years, negatively affected both BMD and TBS [ 147 ]. BMD significantly decreased by 6.1% and TBS by 2.1%, independent of BMD. The loss of TBS was more pronounced during the first year of treatment with a slowing thereafter, whereas the annual loss of BMD continued for up to 4 years.

Glucocorticoids

Prolonged use of glucocorticoids increases fracture risk [ 148 ]. Previous studies have demonstrated that glucocorticoids can weaken bone microarchitecture, for example, through a major loss of trabecular connectivity [ 149 , 150 ], with disease mechanisms involving increased osteoclastogenesis and apoptosis of osteoblasts and osteocytes [ 151 ]. Three studies investigated the effect of glucocorticoid treatment on TBS, and all reported significant reductions ranging from − 3 to − 10%/12 months, with decreases in BMD ranging from − 1.7 to 18%/12 months [ 152 , 153 , 154 ]. The largest reduction in TBS was reported in men and women (mean age 38 y) with rheumatoid arthritis, treated with high-dose compared to lose-dose glucocorticoids over 12 months (− 10% vs. − 1.7%) indicating that the magnitude of the effect is dependent on treatment dose regimen [ 153 ].

Antiosteoporosis treatments in patients with secondary osteoporosis

Ten studies investigated the effects of antiresorptive treatments and five examined anabolic treatments. Of these studies, five included men. Collectively, the effects of treatment on TBS and BMD (Table 3 ), were comparable to those observed in postmenopausal osteoporosis (Table 2 ), reflecting the drug mechanisms of action and duration of treatment.

Antiresorptive agents included bisphosphonates, denosumab and testosterone therapy. One placebo-controlled RCT examined the effect of 12 months testosterone therapy in 197 androgen-deficient men (mean age 54 y) [ 166 ]. No significant differences in TBS were reported between the treatment and placebo groups (1.6% vs. 1.4%), although a significant effect on QCT-derived BMD was observed. In studies of bisphosphonates, the treatment effect, as in postmenopausal women, was one of preservation with no significant changes in either direction reported [ 62 , 162 , 163 , 164 , 167 ]. One RCT over 24 months included 109 women with breast cancer and treated with AI, who received either 35 mg/week risedronate or a placebo [ 164 ]. A significant loss of TBS (− 2.4%) and BMD (− 1.7%) was demonstrated in women receiving the placebo, whereas in women treated with risedronate, there was no change in TBS and an increase in BMD (2.3%). Similar findings were reported in osteopenic/osteoporotic men and women with liver cirrhosis [ 162 ], in women with T2D [ 168 , 169 ], and in corticosteroid-treated women [ 167 ]. On the other hand, TBS significantly increased by 4% in CKD patients treated with denosumab over 12 months [ 165 ].

Studies of anabolic agents included PTH/PTHrP analogues [ 62 , 65 , 168 , 169 , 170 ] and one extension RCT investigated the effects of a sequential anabolic-first treatment regimen [ 169 ]. Overall, anabolic treatments led to increases in TBS ranging from 0.5 to 2.5%/12 months. In the largest RCT and part of the ACTIVE trial, 198 postmenopausal osteoporotic women with T2D received either 80ug abaloparatide, 20ug teriparatide or placebo over 18 months [ 168 ]. The largest increases in TBS and BMD were observed in the abaloparatide group (3.7% and 8.9% respectively) although gains with teriparatide were also significant (2.4% and 2.7% respectively). A separate RCT investigated the efficacy of teriparatide in glucocorticoid-treated women and reported significant increases in TBS of 3.7% and increases in BMD of 10.3% [ 167 ], whereas treatment with alendronate led to increases in BMD (5.5%) and no change in TBS. One study investigated sequential therapy in 32 premenopausal women (mean age 39 y) with severe idiopathic osteoporosis and a history of fragility fractures [ 169 ]. Teriparatide for 12 to 24 months, followed by 24 months of treatment with denosumab led to a sustained mean increase of 5.8% in TBS, comparable to findings in postmenopausal women [ 21 ].

TBS adds value when used with BMD in monitoring skeletal effects of aromatase inhibitors.

TBS adds value when used with BMD in monitoring skeletal effects of glucocorticoids.

Evidence supporting the use of TBS in monitoring response to antiosteoporosis therapy is applicable across both primary and secondary osteoporosis.

Ongoing developments and future research

Recent and ongoing developments in TBS software include the updated TBS algorithm (version 4) that accounts for soft tissue thickness, as an improvement on the current algorithm which estimates tissue thickness using body mass index as a surrogate (version 3.1.2). The updated algorithm has been shown to perform similarly to previous versions of TBS in the prediction of fragility fracture [ 41 ] and be equally or more effective when monitoring changes in TBS in response to antiresorptive and anabolic osteoporosis therapies [ 23 , 24 , 64 , 70 , 71 ]. Given the incorporation of soft tissue adjustment, there is further potential for application in pediatric populations [ 171 ], in patients undergoing significant weight change and in patients with very high or very low BMI [ 172 ], although further studies are required. There are also several recent studies that demonstrate the versatility and expansion of TBS to other skeletal regions including the hip [ 173 ], the distal femur following knee arthroplasty [ 174 ] and lateral vertebral fracture assessment [ 175 ]. Further research in these areas is encouraged.

Conclusions

Evidence supporting the added value of TBS in the assessment and management of osteoporosis has rapidly accumulated since 2015. Collectively, data indicate that TBS enhances fracture risk prediction in both primary and secondary osteoporosis, and across diverse races and ethnicities. Together with FRAX, the inclusion of TBS in conjunction with BMD can provide an improved global assessment of fracture risk, which takes into account the two pillars of fracture resistance (bone mass and bone microarchitecture) and CRFs. Where FRAX is not available, TBS alongside BMD provides a dual skeletal assessment of fracture risk, and the lowest BMD T-score-adjusted for TBS can be input into other fracture risk assessment tools. Limited data suggest that TBS is less influenced by degenerative and inflammatory spinal disease than DXA BMD. Furthermore, TBS has the potential to help inform treatment initiation and the choice of treatment in light of the overall skeletal profile of an individual patient, taking into account both BMD and bone microarchitecture. Including TBS in the monitoring of treatment may be useful for denosumab and anabolic agents, while with bisphosphonates, MHT and SERMs, evidence demonstrates that the effect is mostly one of preservation. The expert consensus statements and operational approach, provided in this paper, can be used to guide the integration of TBS in clinical practice for the assessment and management of osteoporosis.

Peck WA (1993) Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94(6):646–650

Article   Google Scholar  

Kanis JA, McCloskey EV, Harvey NC, Johansson H, Leslie WD (2015) Intervention thresholds and the diagnosis of osteoporosis. J Bone Miner Res 30(10):1747–1753

Article   PubMed   Google Scholar  

Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, Berger ML, Santora AC, Sherwood LM (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 286(22):2815–2822

Article   CAS   PubMed   Google Scholar  

Pasco JA, Seeman E, Henry MJ, Merriman EN, Nicholson GC, Kotowicz MA (2006) The population burden of fractures originates in women with osteopenia, not osteoporosis. Osteoporos Int 17:1404–1409

Sanders KM, Nicholson GC, Watts JJ, Pasco JA, Henry MJ, Kotowicz MA, Seeman E (2006) Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost-effective? Bone 38(5):694–700

Binkley N, Morin SN, Martineau P, Lix LM, Hans D, Leslie WD (2020) Frequency of normal bone measurement in postmenopausal women with fracture: a registry-based cohort study. Osteoporos Int 31:2337–2344

Pothuaud L, Carceller P, Hans D (2008) Correlations between grey-level variations in 2D projection images (TBS) and 3D microarchitecture: applications in the study of human trabecular bone microarchitecture. Bone 42(4):775–787

Pothuaud L, Barthe N, Krieg MA, Mehsen N, Carceller P, Hans D (2009) Evaluation of the potential use of trabecular bone score to complement bone mineral density in the diagnosis of osteoporosis: a preliminary spine bmd–matched, case-control study. J Clin Densitom 12(2):170–176

Hans D, Barthe N, Boutroy S, Pothuaud L, Winzenrieth R, Krieg MA (2011) Correlations between trabecular bone score, measured using anteroposterior dual-energy X-ray absorptiometry acquisition, and 3-dimensional parameters of bone microarchitecture: an experimental study on human cadaver vertebrae. J Clin Densitom 14(3):302–312

Winzenrieth R, Michelet F, Hans D (2013) Three-dimensional (3D) microarchitecture correlations with 2D projection image gray-level variations assessed by trabecular bone score using high-resolution computed tomographic acquisitions: effects of resolution and noise. J Clin Densitom 16(3):287–296

Muschitz C, Kocijan R, Haschka J, Pahr D, Kaider A, Pietschmann P, Hans D, Muschitz GK, Fahrleitner-Pammer A, Resch H (2015) TBS reflects trabecular microarchitecture in premenopausal women and men with idiopathic osteoporosis and low-traumatic fractures. Bone 79:259–266

Ramalho J, Marques IDB, Hans D, Dempster D, Zhou H, Patel P, Pereira RMR, Jorgetti V, Moyses RMA, Nickolas TL (2018) The trabecular bone score: Relationships with trabecular and cortical microarchitecture measured by HR-pQCT and histomorphometry in patients with chronic kidney disease. Bone 116:215–220

McCloskey EV, Odén A, Harvey NC, Leslie WD, Hans D, Johansson H, Barkmann R, Boutroy S, Brown J, Chapurlat R, Elders PJ (2016) A meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX. J Bone Miner Res 31(5):940–948

Leslie WD, Shevroja E, Johansson H, McCloskey EV, Harvey NC, Kanis JA, Hans D (2018) Risk-equivalent T-score adjustment for using lumbar spine trabecular bone score (TBS): the Manitoba BMD registry. Osteoporos Int 29:751–758

Article   CAS   PubMed   PubMed Central   Google Scholar  

Harvey NC, Glüer CC, Binkley N, McCloskey EV, Brandi ML, Cooper C, Kendler D, Lamy O, Laslop A, Camargos BM, Reginster JY (2015) Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice. Bone 78:216–224

Choi YJ, Ock SY, Chung YS (2016) Trabecular bone score (TBS) and TBS-adjusted fracture risk assessment tool are potential supplementary tools for the discrimination of morphometric vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Densitom 19(4):507–514

Zhukouskaya VV, Ellen-Vainicher C, Gaudio A, Privitera F, Cairoli E, Ulivieri FM, Palmieri S, Morelli V, Grancini V, Orsi E, Masserini B (2016) The utility of lumbar spine trabecular bone score and femoral neck bone mineral density for identifying asymptomatic vertebral fractures in well-compensated type 2 diabetic patients. Osteoporos Int 27:49–56

Lin YC, Wu J, Kuo SF, Cheung YC, Sung CM, Fan CM, Chen FP, Mhuircheartaigh JN (2020) Vertebral fractures in type 2 diabetes patients: utility of trabecular bone score and relationship with serum bone turnover biomarkers. J Clin Densitom 23(1):37–43

Leslie WD, Majumdar SR, Morin SN, Hans D, Lix LM (2017) Change in trabecular bone score (TBS) with antiresorptive therapy does not predict fracture in women: the Manitoba BMD cohort. J Bone Miner Res 32(3):618–623

McClung MR, Lippuner K, Brandi ML, Zanchetta JR, Bone HG, Chapurlat R, Hans D, Wang A, Zapalowski C, Libanati C (2017) Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis. Osteoporos Int 28:2967–2973

Tsai JN, Jiang LA, Lee H, Hans D, Leder BZ (2017) Effects of teriparatide, denosumab, or both on spine trabecular microarchitecture in DATA-switch: a randomized controlled trial. J Clin Densitom 20(4):507–512

Article   PubMed   PubMed Central   Google Scholar  

Jeong C, Kim J, Lim Y, Ha J, Kang MI, Baek KH (2021) Effect of Romosozumab on Trabecular bone score compared to anti-resorptive agents in postmenopausal women with osteoporosis. Journal of bone metabolism 28(4):317

Cosman F, Hans D, Shevroja E, Mitlak Wang Y, B, (2023) Effect of abaloparatide on bone microarchitecture assessed by trabecular bone score in women with osteoporosis: post hoc analysis of ACTIVE and ACTIVExtend. J Bone Mineral Res 38(4):464–470

Article   CAS   Google Scholar  

Hans D, McDermott M, Huang S, Kim M, Shevroja E, McClung M (2023) Long-term effect of denosumab on bone microarchitecture as assessed by tissue thickness–adjusted trabecular bone score in postmenopausal women with osteoporosis: results from FREEDOM and its open-label extension. Osteo Int 34(6):1075–1084

Kanis JA, Norton N, Harvey NC, Jacobson T, Johansson H, Lorentzon M, McCloskey EV, Willers C, Borgström F (2021) SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos 16(1):82

Kanis JA, Harvey NC, Johansson H, Liu E, Vandenput L, Lorentzon M, Leslie WD, McCloskey EV (2020) A decade of FRAX: how has it changed the management of osteoporosis? Aging Clin Exp Res 32:187–196

Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 21;6(7):e1000097

Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, Nasser M, Meerpohl J, Post PN, Kunz R, Brozek J (2013) GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol 66(7):719–725

Holloway KL, De Abreu LL, Hans D, Kotowicz MA, Sajjad MA, Hyde NK, Pasco JA (2018) Trabecular bone score in men and women with impaired fasting glucose and diabetes. Calcif Tissue Int 102:32–40

Martineau P, Leslie WD, Johansson H, Oden A, McCloskey EV, Hans D, Kanis JA (2017) Clinical utility of using lumbar spine trabecular bone score to adjust fracture probability: the Manitoba BMD cohort. J Bone Miner Res 32(7):1568–1574

Martineau P, Leslie WD, Johansson H, Harvey NC, McCloskey EV, Hans D, Kanis JA (2018) In which patients does lumbar spine trabecular bone score (TBS) have the largest effect? Bone 113:161–168

Li G, Leslie WD, Kovacs CS, Prior J, Josse RG, Towheed T, Davison KS, Thabane L, Papaioannou A, Levine MA, Goltzman D (2020) Combining frailty and trabecular bone score did not improve predictive accuracy in risk of major osteoporotic fractures. J Bone Miner Res 35(6):1058–1064

Leslie WD, Hans D, Silva BC (2023) Fracture prediction from trabecular bone score is unaffected by anti-resorptive treatment: a registry-based cohort study. J Clin Densitom 26(1):10–15

Su Y, Leung J, Hans D, Aubry-Rozier B, Kwok T (2017) Added clinical use of trabecular bone score to BMD for major osteoporotic fracture prediction in older Chinese people: the Mr. OS and Ms. OS cohort study in Hong Kong. Osteoporosis International 28:151–160

Su Y, Leung J, Hans D, Lamy O, Kwok T (2017) The added value of trabecular bone score to FRAX® to predict major osteoporotic fractures for clinical use in Chinese older people: the Mr. OS and Ms. OS cohort study in Hong Kong. Osteoporos Int 28:111–117

Iki M, Fujita Y, Tamaki J, Kouda K, Yura A, Sato Y, Moon JS, Winzenrieth R, Okamoto N, Kurumatani N (2015) Trabecular bone score may improve FRAX® prediction accuracy for major osteoporotic fractures in elderly Japanese men: the Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) Cohort Study. Osteoporos Int 26:1841–1848

Tamaki J, Iki M, Sato Y, Winzenrieth R, Kajita E, Kagamimori S, for the JPOS Study Group (2019) Does Trabecular Bone Score (TBS) improve the predictive ability of FRAX® for major osteoporotic fractures according to the Japanese Population-Based Osteoporosis (JPOS) cohort study? J Bone Min Metabol 37:161–170

Kim H, Kim JH, Kim MJ, Hong AR, Choi H, Ku E, Lee JH, Shin CS, Cho NH (2020) Low predictive value of FRAX adjusted by trabecular bone score for osteoporotic fractures in korean women: a community-based cohort study. Endocrinol Metab 35(2):359–366

Kužma M, Hans D, Koller T, Némethová E, Jackuliak P, Killinger Z, Resch H, Payer J (2018) Less strict intervention thresholds for the FRAX and TBS-adjusted FRAX predict clinical fractures in osteopenic postmenopausal women with no prior fractures. J Bone Miner Metab 36:580–588

Popp AW, Meer S, Krieg MA, Perrelet R, Hans D, Lippuner K (2016) Bone mineral density (BMD) and vertebral trabecular bone score (TBS) for the identification of elderly women at high risk for fracture: the SEMOF cohort study. Eur Spine J 25:3432–3438

Shevroja E, Aubry-Rozier B, Hans G, Gonzalez-Rodriguez E, Stoll D, Lamy O, Hans D (2019) Clinical performance of the updated trabecular bone score (TBS) algorithm, which accounts for the soft tissue thickness: The OsteoLaus study. J Bone Min Res 34(12):2229–2237

Shevroja E, Mo Costabella F, Gonzalez Rodriguez E, Lamy O, Hans D (2022) The fracture predictive ability of lumbar spine BMD and TBS as calculated based on different combinations of the lumbar spine vertebrae. Archives Osteoporosis 17(1):83

Sakulpisuti C, Sritara C, Kositwattanarerk A, Fuangfa P, Suppasilp C, Vathesatogkit P, Matchariyakul D, Ongphiphadhanakul B, Sritara P (2022) Bone mineral density and trabecular bone score in predicting vertebral fractures in male employees of the electricity generating authority of Thailand. J Osteoporos.  https://doi.org/10.1155/2022/6832166

Schousboe JT, Vo T, Taylor BC, Cawthon PM, Schwartz AV, Bauer DC, Orwoll ES, Lane NE, Barrett-Connor E, Ensrud KE, Osteoporotic Fractures in Men (MrOS) Study Research Group (2016) Prediction of incident major osteoporotic and hip fractures by trabecular bone score (TBS) and prevalent radiographic vertebral fracture in older men. J Bone Min Res 31(3):690–697

Schousboe JT, Vo TN, Langsetmo L, Taylor BC, Cawthon PM, Schwartz AV, Bauer DC, Orwoll ES, Lane NE, Barrett-Connor E, Ensrud KE (2017) Association of trabecular bone score (TBS) with incident clinical and radiographic vertebral fractures adjusted for lumbar spine BMD in older men: a prospective cohort study. J Bone Miner Res 32(7):1554–1558

McCloskey EV, Odén A, Harvey NC, Leslie WD, Hans D, Johansson H, Kanis JA (2015) Adjusting fracture probability by trabecular bone score. Calcif Tissue Int 96:500–509

Chan DC, McCloskey EV, Chang CB, Lin KP, Lim LC, Tsai KS, Yang RS (2017) Establishing and evaluating FRAX® probability thresholds in Taiwan. J Formos Med Assoc 116(3):161–168

Hans D, Goertzen AL, Krieg MA, Leslie WD (2011) Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study. J Bone Miner Res 26(11):2762–2769

Leslie WD, Aubry-Rozier B, Lix LM, Morin SN, Majumdar SR, Hans D (2014) Spine bone texture assessed by trabecular bone score (TBS) predicts osteoporotic fractures in men: the Manitoba Bone Density Program. Bone 67:10–14

LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, Siris ES (2022) The clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 33(10):2049–2102

Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, Hanley DA, Hodsman A, Jamal SA, Kaiser SM, Kvern B (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182(17):1864–1873

Compston J, Bowring C, Cooper A, Cooper C, Davies C, Francis R, Kanis JA, Marsh D, McCloskey EV, Reid DM, Selby P (2013) Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas 75(4):392–396

Boutroy S, Hans D, Sornay-Rendu E, Vilayphiou N, Winzenrieth R, Chapurlat R (2013) Trabecular bone score improves fracture risk prediction in non-osteoporotic women: the OFELY study. Osteoporos Int 24:77–85

Shevroja E (2020) Trabecular Bone Score (TBS): the pathway from bone experiments to a validated clinical use. PhD Thesis – UNIL-CHUV. https://serval.unil.ch/en/notice/serval:BIB_55425DC59F33 . Accessed 12 Jan 2023

Briot K, Paternotte S, Kolta S, Eastell R, Reid DM, Felsenberg D, Glüer CC, Roux C (2013) Added value of trabecular bone score to bone mineral density for prediction of osteoporotic fractures in postmenopausal women: the OPUS study. Bone 57(1):232–236

Nassar K, Paternotte S, Kolta S, Fechtenbaum J, Roux C, Briot K (2014) Added value of trabecular bone score over bone mineral density for identification of vertebral fractures in patients with areal bone mineral density in the non-osteoporotic range. Osteoporos Int 25:243–249

Kanis JA, Harvey NC, Cooper C, Johansson H, Odén A, McCloskey EV, Advisory Board of the National Osteoporosis Guideline Group (2016) A systematic review of intervention thresholds based on FRAX: a report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Archives Osteoporosis 11:1–48

Di Gregorio S, Del Rio L, Rodriguez-Tolra J, Bonel E, García M, Winzenrieth R (2015) Comparison between different bone treatments on areal bone mineral density (aBMD) and bone microarchitectural texture as assessed by the trabecular bone score (TBS). Bone 75:138–143

Shin MS, Cho EH, Kim HY (2017) Longitudinal change in trabecular bone score during and after treatment of osteoporosis in postmenopausal Korean women. Journal of Bone Metabolism 24(2):117–124

Sooragonda B, Cherian KE, Jebasingh FK, Dasgupta R, Asha HS, Kapoor N, Thomas N, Paul TV (2019) Longitudinal changes in bone mineral density and trabecular bone score following yearly zoledronic acid infusion in postmenopausal osteoporosis—a retrospective-prospective study from southern India. Arch Osteoporos 14:1–5

Miyaoka D, Imanishi Y, Ohara M, Hayashi N, Nagata Y, Yamada S, Mori K, Emoto M, Inaba M (2017) Effects of teriparatide and sequential minodronate on lumbar spine bone mineral density and microarchitecture in osteoporosis. Calcif Tissue Int 101:396–403

Kim J, Kim KM, Lim S, Kang MI, Baek KH, Min YK (2022) Efficacy of bisphosphonate therapy on postmenopausal osteoporotic women with and without diabetes: a prospective trial. BMC Endocr Disord 22(1):1–9

Kang T, Park SY, Lee SH, Park JH Suh SW (2022) Comparison of denosumab and zoledronic acid in postmenopausal women with osteoporosis: bone mineral density (BMD) and Trabecular Bone Score (TBS). J Korean Med Sci 37(13):e68

Hans D, McDermott M, Huang S, Kim M, Shevroja E, McClung M (2023) Long-term effect of denosumab on bone microarchitecture as assessed by tissue thickness-adjusted Trabecular Bone Score (TBS) in Postmenopausal Women with Osteoporosis: Results from the Freedom and Open-Label Extension (OLE). J Clin Densitom 25(2):272

Cipriani C, Pepe J, Silva BC, Rubin MR, Cusano NE, McMahon DJ, Nieddu L, Angelozzi M, Biamonte F, Diacinti D, Hans D (2018) Comparative effect of rhPTH (1–84) on bone mineral density and trabecular Bone score in hypoparathyroidism and postmenopausal osteoporosis. J Bone Miner Res 33(12):2132–2139

Bilezikian JP, Hattersley G, Fitzpatrick LA, Harris AG, Shevroja E, Banks K, Leder BZ, Zanchetta JR, Hans D (2018) Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial. Osteoporos Int 29:323–328

Chen FP, Fu TS, Lin YC, Sung CM, Huang MH, Lin YJ (2022) Association between P1NP and bone strength in postmenopausal women treated with teriparatide. Taiwan J Obstet Gynecol 61(1):91–95

Sandeep NV, Joseph A, Cherian KE, Kapoor N, Paul TV (2022) Impact of teriparatide therapy in Indian postmenopausal women with osteoporosis with regard to DXA-derived parameters. Therapeutic Adv Endocrinol Metabol 13:20420188221112904

Leslie WD, Goel H, Binkley N, McCloskey EV, Hans D (2023) Contributions of clinical and technical factors to longitudinal change in trabecular bone score and bone density: a registry-based individual-level analysis. J Bone Miner Res 38:512–521

Hans D, Shevroja E, McDermott M, Huang S, Kim M, McClung M (2022) Updated trabecular bone score accounting for the soft tissue thickness (TBSTT) demonstrated significantly improved bone microstructure with denosumab in the FREEDOM TBS post hoc analysis. Osteoporos Int 33(12):2517–2525

McClung M, Betah D, Leder B, Kendler D, Oates M, Timoshanko J, and Wang Y (2022) Effect of romosozumab on bone microarchitecture as assessed by tissue thickness–adjusted trabecular bone score in postmenopausal women with osteoporosis: results from the ARCH study. https://eposters.asbmr.org/asbmr/2022/eposter/368700 . Accessed 12 Jan 2023

Baron R, Ferrari S, Russell RGG (2011) Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 48(4):677–692

Moreira CA, Dempster DW (2017) Histomorphometric changes following treatment for osteoporosis. J Endocrinol Invest 40:895–897

Wang L, Huang B, Chen X, Su J (2020) New insight into unexpected bone formation by denosumab. Drug Discovery Today 25(11):1919–1922

Ferrari SL, Abrahamsen B, Napoli N, Akesson K, Chandran M, Eastell R, El-Hajj Fuleihan G, Josse R, Kendler D, Kraenzlin M, Suzuki A (2018) Diagnosis and management of bone fragility in diabetes: an emerging challenge. Osteoporos Int 29:2585–2596

Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF (2003) Recombinant human parathyroid hormone (1–34)[teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18(11):1932–1941

Chavassieux P, Chapurlat R, Portero-Muzy N, Roux JP, Garcia P, Brown JP, Libanati C, Boyce RW, Wang A, Grauer A (2019) Bone-forming and antiresorptive effects of romosozumab in postmenopausal women with osteoporosis: bone histomorphometry and microcomputed tomography analysis after 2 and 12 months of treatment. J Bone Miner Res 34(9):1597–1608

Genant HK, Engelke K, Bolognese MA, Mautalen C, Brown JP, Recknor C, Goemaere S, Fuerst T, Yang YC, Grauer A, Libanati C (2017) Effects of romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone mass. J Bone Miner Res 32(1):181–187

Kanis JA, Harvey NC, McCloskey E, Bruyère O, Veronese N, Lorentzon M, Cooper C, Rizzoli R, Adib G, Al-Daghri N, Campusano C (2020) Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int 31:1–12

Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CA (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375(16):1532–1543

Curtis EM, Reginster JY, Al-Daghri N, Biver E, Brandi ML, Cavalier E, Hadji P, Halbout P, Harvey NC, Hiligsmann M, Javaid MK (2022) Management of patients at very high risk of osteoporotic fractures through sequential treatments. Aging Clin Exp Res 34(4):695–714

Kanis JA, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF) (2019) Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Calcified Tissue Int 104:235–238

Kanis JA, McCloskey EV, Harvey NC, Cooper C, Rizzoli R, Dawson-Hughes B, Maggi S, Reginster JY (2023) The need to distinguish intervention thresholds and diagnostic thresholds in the management of osteoporosis. Osteoporos Int 34(1):1–9

Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen TV (2008) Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int 19:1431–1444

Shepherd JA, Lu Y, Wilson K, Fuerst T, Genant H, Hangartner TN, Wilson C, Hans D, Leib ES (2006) Cross-calibration and minimum precision standards for dual-energy X-ray absorptiometry: the 2005 ISCD Official Positions. J Clin Densitom 9(1):31–36

Krueger D, Libber J, Binkley N (2015) Spine trabecular bone score precision, a comparison between GE lunar standard and high-resolution densitometers. J Clin Densitom 18(2):226–232

Bréban S, Briot K, Kolta S, Paternotte S, Ghazi M, Fechtenbaum J, Roux C (2012) Identification of rheumatoid arthritis patients with vertebral fractures using bone mineral density and trabecular bone score. J Clin Densitom 15(3):260–266

Dufour R, Winzenrieth R, Heraud A, Hans D, Mehsen N (2013) Generation and validation of a normative, age-specific reference curve for lumbar spine trabecular bone score (TBS) in French women. Osteoporosis International 24:2837–2846

Messina C, Buonomenna C, Menon G, Magnani S, Albano D, Gitto S, Ulivieri FM, Sconfienza LM (2019) Fat mass does not increase the precision error of trabecular bone score measurements. J Clin Densitom 22(3):359–366

Kang KY, Ju JH, Park SH, Hong YS (2020) Longitudinal association between trabecular bone loss and disease activity in axial spondyloarthritis: a 4-year prospective study. J Rheumatol 47(9):1330–1337

Guan WM, Pan W, Yu W, Cao W, Lin Q, Zhang ZZ, Song XJ, Li YL, Tian JP, Xu Y, Li TS (2021) Changes in trabecular bone score and bone mineral density in Chinese HIV-Infected individuals after one year of antiretroviral therapy. Journal of Orthopaedic Translation 29:72–77

Leslie WD, Aubry-Rozier B, Lamy O, Hans D (2013) TBS (trabecular bone score) and diabetes-related fracture risk. The J Clin Endocrinol Metabol 98(2):602–609

Carnevale V, Romagnoli E, D’Erasmo L, D’Erasmo E (2014) Bone damage in type 2 diabetes mellitus. Nutr Metab Cardiovasc Dis 24(11):1151–1157

Dhaliwal R, Cibula D, Ghosh C, Weinstock RS, Moses AM (2014) Bone quality assessment in type 2 diabetes mellitus. Osteoporosis International 25:1969–1973

Kim JH, Choi HJ, Ku EJ, Kim KM, Kim SW, Cho NH, Shin CS (2015) Trabecular bone score as an indicator for skeletal deterioration in diabetes. J Clin Endocrinol Metab 100(2):475–482

Vlassara H, Brownlee M, Cerami A (1988) Specific macrophage receptor activity for advanced glycosylation end products inversely correlates with insulin levels in vivo. Diabetes 37(4):456–461

Tang SY, Zeenath U, Vashishth D (2007) Effects of non-enzymatic glycation on cancellous bone fragility. Bone 40(4):1144–1151

Jackuliak P, Kužma M, Killinger Z, Payer J (2019) Good long-term glycemic compensation is associated with better trabecular bone score in postmenopausal women with type 2 diabetes. Physiol Res 30;68(Suppl 2):S149–S156

Bonaccorsi G, Fila E, Messina C, Maietti E, Ulivieri FM, Caudarella R, Greco P, Guglielmi G (2017) Comparison of trabecular bone score and hip structural analysis with FRAX® in postmenopausal women with type 2 diabetes mellitus. Aging Clin Experiment Res 29:951–957

Leslie WD, Johansson H, McCloskey EV, Harvey NC, Kanis JA, Hans D (2018) Comparison of methods for improving fracture risk assessment in diabetes: the Manitoba BMD Registry. J Bone Min Res 33(11):1923–1930

Yamamoto M, Yamauchi M, Sugimoto T (2019) Prevalent vertebral fracture is dominantly associated with spinal microstructural deterioration rather than bone mineral density in patients with type 2 diabetes mellitus. PLoS One 14(9):e0222571

Gani LU, Saripalli KR, Fernandes K, Leong SF, Tsai KT, Tan PT, Chong LR, King TF (2020) Bone mineral density and trabecular bone score in elderly type 2 diabetes Southeast Asian patients with severe osteoporotic hip fractures. PLoS ONE 15(11):e0241616

Paul J, Devarapalli V, Johnson JT, Cherian KE, Jebasingh FK, Asha HS, Kapoor N, Thomas N, Paul TV (2021) Do proximal hip geometry, trabecular microarchitecture, and prevalent vertebral fractures differ in postmenopausal women with type 2 diabetes mellitus? A cross-sectional study from a teaching hospital in southern India. Osteo Int 32(8):1585–1593

Belaya ZE, Hans D, Rozhinskaya LY, Dragunova NV, Sasonova NI, Solodovnikov AG, Tsoriev TT, Dzeranova LK, Melnichenko GA, Dedov II (2015) The risk factors for fractures and trabecular bone-score value in patients with endogenous Cushing’s syndrome. Arch Osteoporos 10:1–9

Paggiosi MA, Peel NFA, Eastell R (2015) The impact of glucocorticoid therapy on trabecular bone score in older women. Osteoporos Int 26:1773–1780

Kim D, Cho SK, Kim JY, Choi YY, Sung YK (2016) Association between trabecular bone score and risk factors for fractures in Korean female patients with rheumatoid arthritis. Modern Rheumatol 26(4):540–545

Florez H, Hernández-Rodríguez J, Muxi A, Carrasco JL, Prieto-González S, Cid MC, Espinosa G, Gómez-Puerta JA, Monegal A, Guañabens N, Peris P (2020) Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosis. Rheumatology 59(7):1574–1580

Lee KA, Kim J, Kim HJ, Kim HS (2021) Discriminative ability of trabecular bone score over bone mineral density for vertebral and fragility fracture in patients treated with long-term and low-dose glucocorticoid. Int J Rheum Dis 24(8):1053–1060

Nowakowska-Płaza A, Wroński J, Sudoł-Szopińska I, Głuszko P (2021) Clinical utility of trabecular bone score (tbs) in fracture risk assessment of patients with rheumatic diseases treated with glucocorticoids. Horm Metab Res 53(08):499–503

Naylor KL, Prior J, Garg AX, Berger C, Langsetmo L, Adachi JD, Goltzman D, Kovacs CS, Josse RG, Leslie WD (2016) Trabecular bone score and incident fragility fracture risk in adults with reduced kidney function. Clin J Am Soc Nephrol 11(11):2032–2040

Aleksova J, Kurniawan S, Elder GJ (2018) The trabecular bone score is associated with bone mineral density, markers of bone turnover and prevalent fracture in patients with end stage kidney disease. Osteoporos Int 29:1447–1455

Brunerová L, Lažanská R, Kasalický P, Verešová J, Potočková J, Fialová A, Rychlík I (2018) Predictors of bone fractures in a single-centre cohort of hemodialysis patients: a 2-year follow-up study. Int Urol Nephrol 50:1721–1728

Holloway-Kew KL, Rufus-Membere P, Anderson KB, Betson A, Gaston J, Kotowicz MA, Diez-Perez A, Hyde NK, Pasco JA (2020) Bone material strength index is associated with prior fracture in men with and without moderate chronic kidney disease. Bone 133:115241

Rampersad C, Whitlock RH, Leslie WD, Rigatto C, Komenda P, Bohm C, Hans D, Tangri N (2020) Trabecular bone score in patients with chronic kidney disease. Osteoporosis International 31:1905–1912

Catalano A, Gaudio A, Bellone F, La Fauci MM, Xourafa A, Gembillo G, Basile G, Natale G, Squadrito G, Corica F, Morabito N (2022) Trabecular bone score and phalangeal quantitative ultrasound are associated with muscle strength and fracture risk in hemodialysis patients. Front Endoc.  https://doi.org/10.3389/fendo.2022.940040

Malle O, Bergthaler M, Krisper P, Amrein K, Dimai HP, Kirsch AH, Rosenkranz AR, Pieber T, Obermayer-Pietsch B, Fahrleitner-Pammer A (2022) Usefulness of the trabecular bone score in maintenance dialysis patients: a single center observational study. Wien Klin Wochenschr 134(11–12):442–448

Yun HJ, Ryoo SR, Kim JE, Choi YJ, Park I, Shin GT, Kim H, Jeong JC (2020) Trabecular bone score may indicate chronic kidney disease-mineral and bone disorder (CKD-MBD) phenotypes in hemodialysis patients: a prospective observational study. BMC Nephrol 21:1–10

Kim D, Cho SK, Kim JY, Choi YY, Sung YK (2016) Association between trabecular bone score and risk factors for fractures in Korean female patients with rheumatoid arthritis. Mod Rheumatol 26(4):540–545

Choi YJ, Chung YS, Suh CH, Jung JY, Kim HA (2017) Trabecular bone score as a supplementary tool for the discrimination of osteoporotic fractures in postmenopausal women with rheumatoid arthritis. Medicine.  https://doi.org/10.1097/MD.0000000000008661

Buehring B, Thomas J, Wittkämper T, Baraliakos X, Braun J (2020) Evaluation of the trabecular bone score (TBS) in routine clinical care of patients with inflammatory rheumatic and non-inflammatory diseases: correlation with conventional bone mineral density measurement and prevalence of vertebral fractures. Z Rheumatol 79:1067–1074

Kang KY, Kim IJ, Park SH, Hong YS (2018) Associations between trabecular bone score and vertebral fractures in patients with axial spondyloarthritis. Rheumatology 57(6):1033–1040

Richards C, Hans D, Leslie WD (2020) Trabecular bone score (TBS) predicts fracture in ankylosing spondylitis: the Manitoba BMD registry. J Clin Densitom 23(4):543–548

Killinger Z, Kužma M, Tomková S, Brazdilova K, Jackuliak P, Payer J (2021) Prediction of vertebral fractures by trabecular bone score in patients with ankylosing spondylitis. Physiol Res 70(Suppl 1):S53

Żuchowski P, Dura M, Jeka D, Waszczak-Jeka M (2022) The applicability of trabecular bone score for osteoporosis diagnosis in ankylosing spondylitis. Rheumatol Int 42(5):839–846

Kim HA, Lee HY, Jung JY, Suh CH, Chung YS, Choi YJ (2020) Trabecular bone score is a useful parameter for the prediction of vertebral fractures in patients with polymyalgia rheumatica. J Clin Densitomet 23(3):373–380

Lai EL, Huang WN, Chen HH, Chen JP, Chen DY, Hsieh TY, Hung WT, Lai KL, Lin CT, Tang KT, Chen YM (2020) Degraded microarchitecture by low trabecular bone score is associated with prevalent vertebral fractures in patients with systemic lupus erythematosus. Arch Osteoporos 15:1–7

Lee KA, Kim HJ, Kim HS (2023) Comparison of predictive value of FRAX, trabecular bone score, and bone mineral density for vertebral fractures in systemic sclerosis: a cross-sectional study. Medicine 102(2):e32580

El-Gazzar A, Högler W (2021) Mechanisms of bone fragility: from osteogenesis imperfecta to secondary osteoporosis. Int J Mol Sci 22(2):625

Cooper C, Melton 3rd LJ (1992) Vertebral fractures. BMJ: Brit Med J 20;304(6842):1634–1635

Hayden AC, Binkley N, Krueger D, Bernatz JT, Kadri A, Anderson PA (2022) Effect of degeneration on bone mineral density, trabecular bone score and CT Hounsfield unit measurements in a spine surgery patient population. Osteoporos Int 33(8):1775–1782

Ciullini L, Pennica A, Argento G, Novarini D, Teti E, Pugliese G, Aceti A, Conti FG (2018) Trabecular bone score (TBS) is associated with sub-clinical vertebral fractures in HIV-infected patients. J Bone Miner Metab 36:111–118

Grigorie D, Coles D, Sucaliuc A (2018) Trabecular bone score (TBS) has a poor discriminative power for vertebral fractures in 153 Romanian patients with primary hyperparathyroidism. Acta Endocrinologica (Bucharest) 14(2):208

Watanabe R, Tai N, Hirano J, Ban Y, Inoue D, Okazaki R (2018) Independent association of bone mineral density and trabecular bone score to vertebral fracture in male subjects with chronic obstructive pulmonary disease. Osteoporos Int 29:615–623

Kužma M, Vaňuga P, Ságová I, Pávai D, Jackuliak P, Killinger Z, Binkley NC, Winzenrieth R, Genant HK, Payer J (2019) Non-invasive DXA-derived bone structure assessment of acromegaly patients: a cross-sectional study. Eur J Endocrinol 180(3):201–211

Sakane EN, Vieira MCC, Lazaretti-Castro M, Maeda SS (2019) Predictors of poor bone microarchitecture assessed by trabecular bone score in postsurgical hypoparathyroidism. J Clin Endocrinol Metab 104(12):5795–5803

Teawtrakul N, Chukanhom S, Charoensri S, Somboonporn C Pongchaiyakul C (2020) The trabecular bone score as a predictor for Thalassemia-induced vertebral fractures in northeastern Thailand. Anemia 2020:4634709

Jones AR, Simons K, Harvey S, Grill V (2022) Bone mineral density compared to trabecular bone score in primary hyperparathyroidism. J Clin Med 11(2):330

Ogiso Y, Hanai T, Nishimura K, Miwa T, Maeda T, Imai K, Suetsugu A, Takai K, Shimizu M (2022) Usefulness of the trabecular bone score in assessing the risk of vertebral fractures in patients with cirrhosis. J Clin Med 11(6):1562

Saha S, Mannar V, Kandasamy D, Sreenivas V, Goswami R (2022) Vertebral fractures, trabecular bone score and their determinants in chronic hypoparathyroidism. J Endocrinol Invest 45(9):1777–1786

Vendrami C, Marques-Vidal P, Gonzalez Rodriguez E, Hans D, Waeber G, Lamy O (2022) Thyroid-stimulating hormone is associated with trabecular bone score and 5-year incident fracture risk in euthyroid postmenopausal women: the OsteoLaus cohort. Osteoporos Int 33:195–204

Rubin MR, Dempster DW, Kohler T, Stauber M, Zhou H, Shane E, Nickolas T, Stein E, Sliney J Jr, Silverberg SJ, Bilezikian JP (2010) Three dimensional cancellous bone structure in hypoparathyroidism. Bone 46(1):190–195

Stein EM, Silva BC, Boutroy S, Zhou B, Wang J, Udesky J, Zhang C, McMahon DJ, Romano M, Dworakowski E, Costa AG (2013) Primary hyperparathyroidism is associated with abnormal cortical and trabecular microstructure and reduced bone stiffness in postmenopausal women. J Bone Miner Res 28(5):1029–1040

Tseng OL, Spinelli JJ, Gotay CC, Ho WY, McBride ML, Dawes MG (2018) Aromatase inhibitors are associated with a higher fracture risk than tamoxifen: a systematic review and meta-analysis. Therapeutic advances in musculoskeletal disease 10(4):71–90

Pedrazzoni M, Casola A, Verzicco I, Abbate B, Vescovini R, Sansoni P (2014) Longitudinal changes of trabecular bone score after estrogen deprivation: effect of menopause and aromatase inhibition. J Endocrinol Invest 37:871–874

Mariotti V, Page DB, Davydov O, Hans D, Hudis CA, Patil S, Kunte S, Girotra M, Farooki A, Fornier MN (2017) Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: an enhanced screening approach incorporating trabecular bone score. Journal of bone oncology 7:32–37

Hong AR, Kim JH, Lee KH, Kim TY, Im SA, Kim TY, Moon HG, Han WS, Noh DY, Kim SW, Shin CS (2017) Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer. Osteoporos Int 28:1413–1422

Catalano A, Gaudio A, Agostino RM, Morabito N, Bellone F, Lasco A (2019) Trabecular bone score and quantitative ultrasound measurements in the assessment of bone health in breast cancer survivors assuming aromatase inhibitors. J Endocrinol Invest 42:1337–1343

Messina OD, Vidal M, Torres JAM, Vidal LF, Arguissain C, Pereira RM, Clark P, Cerdas Perez S, Campusano C, Lazaretti-Castro M, Zerbini C, Scali JJ, Mendez Sanchez L, Peralta-Pedrero ML, Cavallo A, Valdivia Ibarra FJ, Hernandez Pérez T (2022) Evidence based Latin American guidelines of clinical practice on prevention, diagnosis, management and treatment of glucocorticoid induced osteoporosis. A 2022 update : this manuscript has been produced under the auspices of the Committee of National Societies (CNS) and the Committee of Scientific Advisors (CSA) of the International Osteoporosis Foundation (IOF). Aging Clin Exp Res 34(11):2591–2602

Chappard D, Legrand E, Basle MF, Fromont P, Racineux JL, Rebel A, Audran M (1996) Altered trabecular architecture induced by corticosteroids: a bone histomorphometric study. J Bone Miner Res 11(5):676–685

Carbonare LD, Arlot ME, Chavassieux PM, Roux JP, Portero NR, Meunier PJ (2001) Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res 16(1):97–103

Adami G, Saag KG (2019) Glucocorticoid-induced osteoporosis: 2019 concise clinical review. Osteoporos Int 30:1145–1156

Chuang MH, Chuang TL, Koo M, Wang YF (2017) Trabecular bone score reflects trabecular microarchitecture deterioration and fragility fracture in female adult patients receiving glucocorticoid therapy: a pre-post controlled study. BioMed Res Int 2017:4210217

Corrado A, Rotondo C, Mele A, Cici D, Maruotti N, Sanpaolo E, Colia R, Cantatore FP (2021) Influence of glucocorticoid treatment on trabecular bone score and bone remodeling regulators in early rheumatoid arthritis. Arthritis Res Ther 23:1–9

Rymuza J, Pelewicz K, Przedlacki J, Miśkiewicz P (2022) Therapy with intravenous methylprednisolone pulses is associated with loss of bone microarchitecture in trabecular bone score-assessment among patients with moderate-to-severe graves’ orbitopathy: a pilot study. Front Endoc 13:893600

Killinger Z, Gajdarova L, Kuzma M, Krajcovicova A, Brazdilova K, Jackuliak P, Payer J (2019) Biologic treatment in comparison to methotrexate has positive effect on trabecular bone score in rheumatoid arthritis patients: 1-year follow-up. Acta Clin Belg 74(2):121–125

Ock SY, Chung YS, Choi YJ (2016) Changes in bone mineral density and trabecular bone score in Graves’ disease patients after anti-thyroid therapy. Osteoporosis and Sarcopenia 2(3):175–179

Godang K, Olarescu NC, Bollerslev J, Heck A (2016) Treatment of acromegaly increases BMD but reduces trabecular bone score: a longitudinal study. Eur J Endocrinol 175(2):155–164

Toussirot É, Mourot L, Dehecq B, Michel F, Wendling D, Grandclément É, Dumoulin G (2017) Paradoxical elevation of serum TRACP5b levels despite increase in lumbar spine bone mineral density during anti-TNFα therapy in patients with inflammatory rheumatic disease: a 2-year prospective assessment of bone mass, bone metabolism, and the trabecular bone score. Europ J Rheumatol 4(3):189

Nordklint AK, Almdal TP, Vestergaard P, Lundby-Christensen L, Boesgaard TW, Breum L, Gade-Rasmussen B, Sneppen SB, Gluud C, Hemmingsen B, Jensen T (2018) The effect of metformin versus placebo in combination with insulin analogues on bone mineral density and trabecular bone score in patients with type 2 diabetes mellitus: a randomized placebo-controlled trial. Osteoporos Int 29:2517–2526

Chung CW, Choi HS, Kong SH, Park YJ, Park DJ, Ahn HY, Cho SW (2021) Measurements of bone health after thyroid-stimulating suppression therapy in postmenopausal women with differentiated thyroid carcinoma: bone mineral density versus the trabecular bone score. J Clin Med 10(9):1964

Yokomoto-Umakoshi M, Umakoshi H, Sakamoto R, Fukumoto T, Ogata M, Nakano Y, Iwahashi N, Kaneko H, Mizoguchi N, Hattori A, Miyazawa T (2021) Role of deteriorated bone quality in the development of osteoporosis in pheochromocytoma and paraganglioma. Bone 142:115607

Librizzi MS, Guadalix S, Martínez-Díaz Guerra G, Allo G, Lora D, Jimenez C, Hawkins F (2016) Trabecular bone score in patients with liver transplants after 1 year of risedronate treatment. Transplant International 29(3):331–337

María RS, Marta PM, Sonia S, Natalia GG, Tamara M, Ignasi T, Maria MG, Jaime RM, Adolfo DP, Joan A, Xavier N (2016) TBS and BMD at the end of AI-therapy: A prospective study of the B-ABLE cohort. Bone 92:1–8

Prasad C, Greenspan SL, Vujevich KT, Brufsky A, Lembersky BC, Van Londen GJ, Jankowitz RC, Puhalla SL, Rastogi P, Perera S (2016) Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: a randomized, controlled clinical trial. Bone 90:123–126

Bonani M, Frey D, Graf N, Wüthrich RP (2019) Effect of denosumab on trabecular bone score in de novo kidney transplant recipients. Nephrol Dial Transplant 34(10):1773–1780

Cauley JA, Ellenberg SS, Schwartz AV, Ensrud KE, Keaveny TM, Snyder PJ (2021) Effect of testosterone treatment on the trabecular bone score in older men with low serum testosterone. Osteoporos Int 32(11):2371–2375

Saag KG, Agnusdei D, Hans D, Kohlmeier LA, Krohn KD, Leib ES, MacLaughlin EJ, Alam J, Simonelli C, Taylor KA, Marcus R (2016) Trabecular bone score in patients with chronic glucocorticoid therapy–induced osteoporosis treated with alendronate or teriparatide. Arthritis & Rheumatology 68(9):2122–2128

Dhaliwal R, Hans D, Hattersley G, Mitlak B, Fitzpatrick LA, Wang Y, Schwartz AV, Miller PD, Josse RG (2020) Abaloparatide in postmenopausal women with osteoporosis and type 2 diabetes: a post hoc analysis of the ACTIVE study. JBMR plus 4(4):e10346

Shane E, Shiau S, Recker RR, Lappe JM, Agarwal S, Kamanda-Kosseh M, Bucovsky M, Stubby J, Cohen A (2022) Denosumab after teriparatide in premenopausal women with idiopathic osteoporosis. J Clin Endocrinol Metab 107(4):e1528–e1540

Munekawa C, Hashimoto Y, Kitagawa N, Osaka T, Hamaguchi M, Fukui M (2022) Effect of teriparatide on bone mineral density and trabecular bone score in type 2 diabetic patients with osteoporosis: A retrospective cohort study. Medicina 58(4):481

Kalkwarf HJ, Shepherd JA, Hans D, Gonzalez Rodriguez E, Kindler JM, Lappe JM, Oberfield S, Winer KK, Zemel BS (2022) Trabecular bone score reference values for children and adolescents according to age, sex, and ancestry. J Bone Miner Res 37(4):776–785

Bonaccorsi G, Cafarelli FP, Cervellati C, De Guio F, Greco P, Giganti M, Guglielmi G (2020) A new corrective model to evaluate TBS in obese post-menopausal women: a cross-sectional study. Aging Clin Exp Res 32:1303–1308

Haeri NS, Perera S, Ferreiro I, Hans D, Greenspan SL (2022) Trabecular bone score in the hip: a new method to examine hip bone microarchitecture—a feasibility study. Arch Osteoporos 17(1):126

White R, Krueger D, De Guio F, Michelet F, Hans D, Anderson P, Binkley N (2021) An exploratory study of the texture research investigational platform (TRIP) to evaluate bone texture score of distal femur DXA scans–a TBS-based approach. J Clin Densitom 24(1):112–117

Shevroja E, White R, Lamy O, Krueger D, Hans D, Binkley N (2022) Bone texture assessment on lateral VFAs using the Texture Research Investigational Platform (TRIP) and its fracture discrimination ability. J Clin Densitom 25(4):599–605

Download references

Acknowledgements

We gratefully acknowledge information on technical considerations from Medimaps Group. The ESCEO Working Group was funded by the ESCEO. The ESCEO receives unrestricted educational grants to support its educational and scientific activities from non-governmental organisations, not-for-profit organisations, non-commercial or corporate partners. The choice of topics, participants, content and agenda of the Working Groups as well as the writing, editing, submission and reviewing of the manuscript are the sole responsibility of the ESCEO, without any influence from third parties.

Author information

Authors and affiliations.

Interdisciplinary Center for Bone Diseases, Lausanne University Hospital and University of Lausanne, 1011, Lausanne, Switzerland

Enisa Shevroja & Olivier Lamy

World Health Organization Collaborating Center for Epidemiology of Musculoskeletal Health and Aging, Liège, Belgium

Jean-Yves Reginster

Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart Tilman B23, 4000, Liège, Belgium

Biochemistry Department, College of Science, King Saud University, 11451, Riyadh, Kingdom of Saudi Arabia

Nasser Al-Daghri

Osteoporosis and Bone Metabolism Unit, Department of Endocrinology, Singapore General Hospital, ACADEMIA, 20, College Road, Singapore, 169856, Singapore

Manju Chandran

Service de Médecine Interne Et Gériatrie, CHU Nord Chemin Des Bourrely, Marseille, France

Anne-Laurence Demoux-Baiada

Spokane Strides for Strong Bones, Medical Director, West Coast Bone Health CME TeleECHO, Spokane, WA, USA

Lynn Kohlmeier

Faculty of Medicine, Quartier Hospital, Liège, Belgium

Marie-Paule Lecart

IRO Medical Research Center, Buenos Aires and Rheumatology Section, Cosme Argerich, Buenos Aires, Argentina

Daniel Messina

Rede Materdei de Saúde - Hospital Santo Agostinho - Densitometry Unit Coordinator, Belo Horizonte, Brazil

Bruno Muzzi Camargos

5th Department of Internal Medicine, Comenius University Faculty of Medicine, University Hospital, Bratislava, Slovakia

Juraj Payer

Ružinovská 6, 82101, Bratislava, Slovakia

Department of Physical Medicine and Rehabilitation, Cerrahpaşa School of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey

Sansin Tuzun

Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties “G. D’Alessandro”, University of Palermo, 90127, Palermo, Italy

Nicola Veronese

MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, SO16 6YD, UK

Cyrus Cooper & Nicholas C. Harvey

NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK

NIHR Biomedical Research Centre, University of Oxford, Oxford, UK

Cyrus Cooper

Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK

Eugene V. McCloskey

MRC Versus Arthritis Centre for Integrated Research in Musculoskeletal Ageing, Mellanby Centre for Musculoskeletal Research, University of Sheffield, Sheffield, UK

You can also search for this author in PubMed   Google Scholar

Corresponding author

Correspondence to Nicholas C. Harvey .

Ethics declarations

Consents and ethics approval.

This narrative article contains no original data and thus issues of ethics, informed consent and patient confidentiality do not apply.

Conflict of interest

J.Y.R. has received fees for lectures or advisory boards from IBSA-Genevrier, Mylan, Radius Health, Pierre Fabre, Faes Pharma, Rejuvinate Biomed, Teva, Theramex, Pfizer, Mithra Pharmaceuticals, CNIEL, Dairy Research Council, Nutricia, Danone and Agnovos, and industry grants (all through institution) from IBSA-Genevrier, Mylan, CNIEL, Radius Health and TRB, outside the submitted work.

C.C. reports personal fees from ABBH, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier and Takeda, outside the submitted work.

N.C.H. reports personal fees, consultancy, lecture fees and honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, UCB, Kyowa Kirin, Servier, Shire, Theramex, Consilient Healthcare and Internis Pharma, outside the submitted work.

L.K. reports lecture fees and honoraria from Alexion, Amgen, Ascendis, Medimaps (2 single presentations), and Radius, outside the submitted work.

E.V.M reports consultancy, advisory boards and or lecture fees from Amgen, AstraZeneca, Consilient Healthcare, Fresenius Kabi, GSK, Hologic, Internis, Lilly, ObsEva, Pfizer, UCB. Additional research support from Versus Arthritis, I3 Innovus, MRC and IOF.

N.V. reports personal fees from IBSA, Mylan, Viatris, Fidia, MSD outside of the submitted work.

N.A-D., D.M.C., M.C., A-L.D., O.L., D.M., J.P., M-P.L., S.T. declare no conflicts of interest.

Additional information

Publisher's note.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Eugene V. McCloskey and Nicholas C. Harvey are joint senior authors.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 28 KB)

Appendix 1. operational considerations based on approved statements and expert opinion for the integration of tbs in clinical practice.

Trabecular bone score (TBS) is grey scale texture measure that correlates with bone microarchitecture, which can be used alongside FRAX and BMD to enhance the assessment of fracture risk and to inform treatment initiation and monitoring. The following guidance can be used to facilitate the integration of TBS in clinical practice in alignment with clinical workflow (see Appendix Fig. 2 ).

Integration of TBS into the clinical workflow

Indications for the use of TBS (adapted from ISCD, 2019; Kanis et al., 2019)

If FRAX (without BMD) indicates intermediate risk of fracture;

In women aged 65 years or over, and men aged 70 years or over, for routine bone health monitoring;

In women and men aged under 65 and 70 years respectively, TBS is recommended alongside BMD, if they have a risk factor for low bone mass such as low body weight, prior fracture, high-risk medication use, or a disease or condition associated with bone loss;

Adults with a fragility fracture;

Adults with a disease or condition associated with secondary osteoporosis;

Adults taking a medication associated with secondary osteoporosis;

Adults who are being considered for pharmacological treatment;

Adults receiving treatment, to monitor treatment effectiveness;

Adults not receiving osteoporosis treatment, when evidence of bone fragility would lead to treatment.

Image acquisition and quality assessment (technical considerations)

A DXA scanner calibration with a dedicated fractal phantom is required for TBS software installations and when there is a change in the DXA system, in order to clinically interpret the data;

When a DXA system is upgraded or replaced, it is strongly recommended that a new baseline TBS measurement is set for patients under treatment monitoring;

Change in scan mode may impact TBS outcomes. This can be mitigated by ensuring correct measurement and data entry of height and weight, and avoidance of change in scan mode for longitudinal monitoring, unless indicated by the DXA manufacturer;

Vertebrae affected by structural anomalies should be excluded from BMD analysis in accordance with ISCD protocol. Vertebrae excluded for BMD analysis are also excluded for TBS, e.g. sclerotic lesions, osteophytes, syndesmophytes, laminectomy and fracture;

Spinal degenerative changes minimally impact TBS, unlike BMD. As such, it is not unusual to observe discordance between spine TBS (lower) and BMD (higher);

If two or more vertebrae are excluded, neither BMD nor TBS can be used for diagnosis;

When a combination of vertebrae other than L1-L4 is used, combination-specific threshold adjustments are automatically applied in the current TBS iNsight version (3.1 and higher).

The currently available TBS software is valid for use in individuals within the BMI range of 15 to 37 kg.m −2 . Interpretation of TBS results outside of this range should be made with caution.

Bone health assessment

In the assessment of bone health, TBS can be used alongside BMD to provide additional information relating to bone microarchitecture;

The ‘Bone Resilience Index’ is an interpretive tool provided by the manufacturer, comprising combinations of categories of BMD (normal, osteopenic or osteoporosis) and TBS (normal, partially degraded or degraded);

Discordance between BMD and TBS (for example, normal BMD and degraded TBS), should prompt consideration of further clinical evaluation for possible causes of secondary osteoporosis;

Vertebral fracture assessment (VFA) should be considered for osteopenic patients with degraded TBS.

Fracture risk assessment

TBS can be used in the assessment of fracture risk using FRAX-adjusted for TBS directly OR indirectly by using the femoral neck BMD T-score-adjusted for TBS, but not both, to avoid over-adjustment for TBS;

FRAX-adjusted for TBS can be used to adjust the probability of MOF or hip fracture, for bone microarchitecture, in men and women aged 40 to 90 years. The adjusted FRAX probabilities can then be compared to local or national intervention thresholds;

In countries and regions where BMD T-score is the primary measure for assessment and reimbursement, BMD T-score-adjusted for TBS can be used;

BMD T-score-adjusted for TBS can be used in fracture prediction models other than FRAX;

The lowest adjusted T-score (lumbar spine, total hip or femoral neck) is used for diagnosis;

Other approaches might include BMD Z-score (age 20 to 49 years) and the risk threshold adjustment (or treatment threshold shift) referring to the lowest BMD T-score adjusted for TBS Z-score;

The selected approach should reflect patient age and country or region-specific guidelines.

Antiosteoporosis treatment initiation, decision-making and monitoring

FRAX-adjusted for TBS or BMD T-score adjusted for TBS can be used to inform treatment initiation, in conjunction with country or region-specific treatment intervention thresholds;

The greatest utility of either TBS adjustment is for individuals who are close to a FRAX or BMD T-score treatment intervention threshold;

Patients with low TBS who lie below but near the treatment threshold should be considered for an earlier assessment and lifestyle advice;

FRAX-adjusted for TBS can be used to guide the choice of anti-osteoporosis treatment in the framework of ESCEO-IOF recommendations on categorization to low, high or very high fracture risk (with the latter category directed to anabolic first regimens);

Since TBS captures elements of bone microarchitecture, conceptually, a low (degraded or partially degraded) TBS might support the use of treatments that impact both BMD and bone microarchitecture, for example, long-term denosumab or bone anabolic agents;

Conversely, bisphosphonates, SERMs and MHT might be considered if the treatment goal is preservation of TBS;

Least significant change (LSC) should be used to interpret treatment effect at the individual level, based on the center-specific precision error;

The average of published TBS precision errors and corresponding LSCs (Hologic and GE systems) are 1.37%CV and 3.79% respectively.

If a patient has a significant reduction (exceeding LSC) in TBS during treatment, consider causes of secondary osteoporosis and if an alternative treatment is required;

If a patient has a significant increase (exceeding LSC) in TBS and/or BMD during treatment while not expected given the given drugs and their associated mechanism of action, check for possible technical inaccuracies.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ .

Reprints and permissions

About this article

Shevroja, E., Reginster, JY., Lamy, O. et al. Update on the clinical use of trabecular bone score (TBS) in the management of osteoporosis: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), and the International Osteoporosis Foundation (IOF) under the auspices of WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Aging. Osteoporos Int 34 , 1501–1529 (2023). https://doi.org/10.1007/s00198-023-06817-4

Download citation

Received : 04 April 2023

Accepted : 31 May 2023

Published : 01 July 2023

Issue Date : September 2023

DOI : https://doi.org/10.1007/s00198-023-06817-4

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

• Trabecular bone score
• Osteoporosis
• Find a journal
• Publish with us
• Track your research

Site Search

• About ARPA-E
• Team Directory
• ARPA-E History
• Annual Reports
• Budget Requests
• Apply For Funding
• Authorization
• View Active Programs
• Search Our Programs
• Search Individual Projects
• Interactive Project Map
• Exploratory Topics
• The SCALEUP Program
• OPEN Programs
• Project Guidance
• ARPA-E Technology-to-Market
• Technology Commercialization
• External Engagement Model
• Investor Updates
• ARPA-E News & Media
• Press Releases
• ARPA-E Disruptors
• Publications
• ARPA-E Events
• Energy Innovation Summit
• Careers at ARPA-E
• Job Opportunities
• Life at ARPA-E
• ARPA-E FAQs
• General Questions
• Current Funding Opportunities
• Closed Funding Opportunities

Press Release

ARPA-E Announces Innovation Agreement Outlining Vision for the Future of Electrified Airports at Technology Expo Hosted in San Antonio

Today, the U.S. Department of Energy (DOE) Advanced Research Projects Agency-Energy (ARPA-E), the City of San Antonio Aviation Department and City Public Service Board (CPS Energy), and the University of Texas at San Antonio (UTSA) signed a Memorandum of Understanding (MOU) outlining collective efforts to develop and promote technologies that include, but are not limited to, sustainable aviation, battery technologies and innovative battery storage solutions, enhanced electric vehicle (EV) charging, and power demand management technologies. This agreement marks the first time an international airport will work together with ARPA-E—DOE’s innovation arm—to accelerate the development and deployment of new energy technologies to decarbonize the aviation sector. ARPA-E Director Evelyn Wang, San Antonio Mayor Ron Nirenberg, UTSA President Dr. Taylor Eighmy, and CPS Energy Vice President of Customer Value Karma Nilsson were all present for the signing hosted at Stinson Municipal Airport in San Antonio. “We are excited at this opportunity to collaborate and showcase innovative energy technologies that could transform the future of aviation,” said ARPA-E Director Evelyn N. Wang. “Today’s MOU signing is a step in the right direction to ensuring that these innovative technologies are developed, built, and integrated in America. Our hope is that this partnership will lay the groundwork to enable future electrified airports.” “We are proud to be a part of this innovative initiative that will ultimately benefit the San Antonio community,” said Rudy D. Garza, President and CEO of CPS Energy. “CPS Energy continues to look for ways to participate in electrification projects, especially for critical public infrastructure like the San Antonio International Airport. Projects like these furthers our commitment to finding new and sustainable technologies to enable our growing community and we are excited about the opportunity to work with our community partners to do so.” “This is an important agreement with the potential to shape the aviation industry of the future,” said San Antonio Mayor Ron Nirenberg.  “Researching the decarbonization of aviation and finding new sustainable energy models is important work, and I am proud San Antonio will be playing a leading role in this cutting-edge research.” “This is a unique partnership designed to promote transformative energy technologies and it propels the City of San Antonio’s Aviation Department to the center of innovation,” said Jesus Saenz, Director of Airports, City of San Antonio Aviation Department. “This is an exciting time to be part of the Aviation Team and planning for the future of aviation and our airports.” “This collaborative effort is an incredible opportunity for UTSA to partner with strategic industry leaders in evaluating electric aircraft, advanced energy storage and micro-grid systems to advance the adoption of sustainable multi-modal transportation technologies,” said UTSA President Taylor Eighmy. “Together, this collective will accelerate discoveries that will positively impact the local and regional economies while advancing technologies that change the world.”

To mark this historic milestone, the following ARPA-E-funded project teams were also present to showcase their technologies and share how their innovations could be integrated into future electrified airports:

• Ampaire , who is setting new standards for sustainable air travel and eco-friendly transportation solutions, flew its cutting-edge hybrid electric EEL aircraft and  watch video of the aircraft here ;
• Imagen Energy showcased ultrafast, compact electric vehicle chargers delivering efficient and cost-effective power solutions;
• Natron Energy featured sodium-ion batteries that can safely store energy and efficiently deliver power on demand;
• AutoGrid discussed a distributed energy resource management system that can help grid operators manage energy supply and demand fluctuations; 
• Quidnet Energy brought a wellhead to illustrate a modular geomechanical pumped storage systems that can utilize existing natural resources to store renewable energy over long durations; and
• Texas A&M University Research Team  presented 3D-printed models of a motor and shared concepts for advancing efficiency in electric transportation. 

UTSA and CPS Energy also presented research to leverage a city-scale grid digital twin to evaluate operational efficacy, ensure seamless interoperability, fortify cybersecurity protocols, and assess performance metrics of electric/hybrid aircrafts.

The MOU signed today will enable collaboration to identify research, development, demonstration, and deployment opportunities that will promote sustainable aviation technologies.

# # # 

Press and General Inquiries: 202-287-5440 [email protected]

• Skip to main content
• Keyboard shortcuts for audio player

A professor worried no one would read an algae study. So she had it put to music

Dead fish washed ashore in a red tide in 2018 in Sanibel, Fla. Joe Raedle/Getty Images hide caption

Dead fish washed ashore in a red tide in 2018 in Sanibel, Fla.

An anthropology professor at the University of South Florida recently published a paper she knew barely anyone would read. At least, not outside her field.

The paper, co-authored with three other professors, had to do with the impact of algae blooms and depletion of coral reefs on the region's tourism industry. The work was glum, says Heather O'Leary . It involved tracking visitors' reactions to the environment on social media.

"Part of the data for months was just reading tweets: dead fish, dead fish, dead fish," she recalls. "We were really thinking every day about the Gulf of Mexico and the waters that surround us, especially in St. Pete as a peninsula, about those risks, and the risks to our coastal economy."

The Picture Show

Changing the climate of protest with aerial art.

But attending concerts at USF's School of Music inspired and gladdened her. So she reached out to its director of bands, Matthew McCutchen .

"I'm studying climate change and what's going down at the coral reefs," he remembers her saying. "And I've got all this data and I'd like to know if there's any way that we can turn it into music."

Indeed there was. Composition professor Paul Reller worked with students to map pitch, rhythm and duration to the data. It came alive, O'Leary says, in ways it simply does not on a spreadsheet.

Matthew McCutchen, Heather O'Leary and Hunter Pomeroy at the University of South Florida Symphonic Band & Wind Ensemble show at USF Concert Hall. Aiden Michael McKahan/University of South Florida hide caption

Matthew McCutchen, Heather O'Leary and Hunter Pomeroy at the University of South Florida Symphonic Band & Wind Ensemble show at USF Concert Hall.

"My students were really excited to start thinking about how the other students, the music students, heard patterns that we did not see in some of the repetitions," she says. With music, she added, "you can start to sense with different parts of your mind and your body that there are patterns happening and that they're important."

In this case, she says, the patterns revealed the economic impact of pollution on coastal Florida communities. The complex challenge is a symptom of other, bigger problems. "The world is going to see more and more of these purportedly 'wicked problems,' the ones that take multiple people with different types of training and background to solve," O'Leary says.

Joe's Big Idea

Climate scientist tries arts to stir hearts regarding earth's fate.

The University of South Florida is excited about this composition . Other departments are getting involved, including communications, education and library science. Now, a group of faculty and students are working to bring together music and the environment in related projects, such as an augmented reality experience based on this composition. The group, which calls itself CRESCENDO (Communicating Research Expansively through Sonification and Community-Engaged Neuroaesthetic Data-literacy Opportunities) wants to spread awareness about the algae blooms, data literacy and democratizing science.

Edited for radio and the web by Rose Friedman. Produced for the web by Beth Novey. Produced for the radio by Isabella Gomez Sarmiento.

• science and music
• University of South Florida
• algae bloom